Imprecision	Event	Original Text	English Translation

	Basel, Jul. 1480	“Anno 1480 circa Magdalenae ingens fuit aquarum inundatio. Rhenus in tantum crevit, quod ad lateres usque inferioris muri Minoris Basileae circa litus ascendit. Etiam homines in ponte stantes facile in Reno manus lavare poterunt.” [Bernoulli, 1915, p. 210]	In 1480, around Magdalena('s day) there was a huge flood of waters. The Rhine rose to the sides of the lower walls of Lesser Basel, near the shore. People standing on the bridge could wash their hands in the Rhine.

small	Meiningen, Jan. 1820	“Nachdem (18. Jan.) mehrere Tage strenge Kälte gewesen war, trat Thauwetter ein und am 20. Jan. war in Folge desselben die Werra aus den Ufern getreten daßdas Wasser die Chaussee am obern Rafen überstieg.” (Chronik)	After that for some days strong coldness occurred, and then melting, and as a consequence on 20 January the Werra left its bed and the water exceeded the promenade on the upper stage.

	Szeged, Jul. 1816	“Alább in a Te(kinte)tes N(eme)s Tanácsnak Kegyes rendeléséhez képpest alázatossan jelentem hogy a Tisza vize, a Maros vízének szörnyü és az idein legnagyobb mostani kiöntése miáll szüntelen árad úgy hogy a múlt Julius 8ik napjátúl fogva 2 Hüvelknyire Fölmagossodott melly szerént a Tiszának az idei legnagyobb aradásátúl fogva esett apadása 20 Hüvelknyit tészen. Szeged 12ik Julii 816. Vedres István”	Letter to the Locumtenential Council: Below, following the order of the esteemed noble council, I report that the water of the Tisza, due to the horrible and in this greatest present inundation of the waters of the Maros, is constantly increasing, and so from the (past) 8 July it increased with 2 inches and thus, the total decrease of the water level of the Tisza compared to the highest levels takes 20 inches. Szeged, 12 July 1816. Istvan Vedres

	Basel, Jul. 1570	“Umb dise zeit ist auch der Rhein so großworden/daßer innerhalb der Statt von dreyen Rhein‐Thoren under der Bruck zusamen geflossen/und die Brucken einem Holz‐floßauff dem Wasser gleich gesehen.” [Groß, 1624, p. 210]	Around this time the Rhine was also so large that it flowed together under the bridge through the three Rhine‐gates in the downtown, and the bridge looked like a wooden raft on the river.

medium	Meiningen, Jun. 1816	“Dreimal trat die Werra aus den Ufern; der ganze Grund stand gegen 14 Tage auf dem Halme aus und die wenige Frucht, die man ärndtete und feucht einfuhr, gab schlechtes Brod.” (Chronik, p. 197)	The Werra left its banks three times; water was on the whole ground covering the stalks and the little grain people harvested, gave bad bread.

	Szeged, 1741	“... preter quod enim quod eadem exundatio agris seminaturas Prata et Pendentes in Vinejs agris fructus in Locis praeterea Marusio et Tibisco Vicinis totaliter perfuderit, et in nihilum redegerit etiam in forejs quod Miser Incola n(on) sui sustentatione conservabat inundavit et Usui humani redidit inutile” (CsCP)	..., and beyond that the same inundation completely flooded the arable lands (with crops), pastures, vineyards and orchards along the Maros and Tisza rivers, and gave nothing to people, and became useless for human use.

	Basel, 1268	“Renus crevit usque adeo, quod omnes pontes destruxit.” (Ann., p. 193)	The Rhine rose so much that it destroyed all bridges.

large	Meiningen, May 1818	“Nach anhaltenden Regenwetter trat die Werra aus den Ufern. Am 18. Mai war die Ueberschwemmung am bedeutendsten.” (Chronik, p.205)	After persistent rainy weather the Werra left its banks. The flooding was the most significant on 18 May.

	Szeged, 1731	3o. “Ioanni Hegedüs, ex quo exundatio aquarum modernam Domum residentionalem destruxisset,...” (SzCP)	The house of Janos Hegedüs has been destroyed by the recent flood,...

Event	Original Text	English Translation

Basel, Jul. 1480	“Anno 1480 circa Magdalenae ingens fuit aquarum inundatio. Rhenus in tantum crevit, quod ad lateres usque inferioris muri Minoris Basileae circa litus ascendit. Etiam homines in ponte stantes facile in Reno manus lavare poterunt.” [Bernoulli, 1915, p. 210]	In 1480, around Magdalena('s day) there was a huge flood of waters. The Rhine rose to the sides of the lower walls of Lesser Basel, near the shore. People standing on the bridge could wash their hands in the Rhine.

Meiningen, Jan. 1820	“Nachdem (18. Jan.) mehrere Tage strenge Kälte gewesen war, trat Thauwetter ein und am 20. Jan. war in Folge desselben die Werra aus den Ufern getreten daßdas Wasser die Chaussee am obern Rafen überstieg.” (Chronik)	After that for some days strong coldness occurred, and then melting, and as a consequence on 20 January the Werra left its bed and the water exceeded the promenade on the upper stage.

Szeged, Jul. 1816	“Alább in a Te(kinte)tes N(eme)s Tanácsnak Kegyes rendeléséhez képpest alázatossan jelentem hogy a Tisza vize, a Maros vízének szörnyü és az idein legnagyobb mostani kiöntése miáll szüntelen árad úgy hogy a múlt Julius 8ik napjátúl fogva 2 Hüvelknyire Fölmagossodott melly szerént a Tiszának az idei legnagyobb aradásátúl fogva esett apadása 20 Hüvelknyit tészen. Szeged 12ik Julii 816. Vedres István”	Letter to the Locumtenential Council: Below, following the order of the esteemed noble council, I report that the water of the Tisza, due to the horrible and in this greatest present inundation of the waters of the Maros, is constantly increasing, and so from the (past) 8 July it increased with 2 inches and thus, the total decrease of the water level of the Tisza compared to the highest levels takes 20 inches. Szeged, 12 July 1816. Istvan Vedres

Basel, Jul. 1570	“Umb dise zeit ist auch der Rhein so großworden/daßer innerhalb der Statt von dreyen Rhein‐Thoren under der Bruck zusamen geflossen/und die Brucken einem Holz‐floßauff dem Wasser gleich gesehen.” [Groß, 1624, p. 210]	Around this time the Rhine was also so large that it flowed together under the bridge through the three Rhine‐gates in the downtown, and the bridge looked like a wooden raft on the river.

Meiningen, Jun. 1816	“Dreimal trat die Werra aus den Ufern; der ganze Grund stand gegen 14 Tage auf dem Halme aus und die wenige Frucht, die man ärndtete und feucht einfuhr, gab schlechtes Brod.” (Chronik, p. 197)	The Werra left its banks three times; water was on the whole ground covering the stalks and the little grain people harvested, gave bad bread.

Szeged, 1741	“... preter quod enim quod eadem exundatio agris seminaturas Prata et Pendentes in Vinejs agris fructus in Locis praeterea Marusio et Tibisco Vicinis totaliter perfuderit, et in nihilum redegerit etiam in forejs quod Miser Incola n(on) sui sustentatione conservabat inundavit et Usui humani redidit inutile” (CsCP)	..., and beyond that the same inundation completely flooded the arable lands (with crops), pastures, vineyards and orchards along the Maros and Tisza rivers, and gave nothing to people, and became useless for human use.

Basel, 1268	“Renus crevit usque adeo, quod omnes pontes destruxit.” (Ann., p. 193)	The Rhine rose so much that it destroyed all bridges.

Meiningen, May 1818	“Nach anhaltenden Regenwetter trat die Werra aus den Ufern. Am 18. Mai war die Ueberschwemmung am bedeutendsten.” (Chronik, p.205)	After persistent rainy weather the Werra left its banks. The flooding was the most significant on 18 May.

Szeged, 1731	3o. “Ioanni Hegedüs, ex quo exundatio aquarum modernam Domum residentionalem destruxisset,...” (SzCP)	The house of Janos Hegedüs has been destroyed by the recent flood,...


	n	Minimum	Maximum	Mean	Std Deviation

Age (months)	20	6.00	59.00	39.3500	18.65

Weight (Kg)	20	6.7	23.4	14.9	4.5


		Low prescribers (n = 408)	High prescribers (n = 408)

		Number	Percent	[95% confidence interval]	Number	Percent	[95% confidence interval]

Gender	Female	116	28.4	[24.2–33.1]	118	28.9	[24.6–33.6]

Male	292	71.6	[66.9–75.8]	290	71.1	[66.4–75.4]

Practice location	Rural	110	27.0	[22.8–31.6]	80	19.6	[15.9–23.9]

Urban	298	73.0	[68.4–77.2]	328	80.4	[76.1–84.0]

GP partially particular mode of practice	Yes	40	9.8	[7.2–13.2]	13	3.2	[1.8–5.5]

No	368	90.2	[86.9–92.9]	395	96.8	[94.5–98.2]

Cessation of activity during the year 2010	Yes	7	1.7	[0.8–3.7]	7	1.7	[0.8–3.7]

No	401	98.3	[96.3–99.2]	401	98.3	[96.3–99.2]

		Mean		[Standard deviation]	Mean		[Standard deviation]

Age of GPs		52.6		[9.39]	52.8		[8.10]

Cumulative years of medical practice		19.83		[10.71]	20.5		[9.7146]

Number of consultations and home visits		3,982		[1,994]	3,863		[1,758]

Number of different patients per year		1,106		[538]	1,012		[396]

Number of registered patients		701		[406]	732		[346]

Mean age of patients		46.3		[6.02]	45		[6.1]

Number of patients with low income		60		[79]	45		[48]

Number of patients with chronic disease		145		[91]	144		[80]

Number of days of Sickness certificates prescribed		3,608		[2,537]	3,571		[2,225]

Number of patients prescribed a sickness certificate		100 [64]			94		[50]

Total volume of reimbursement (number of units)		28,247		[17,316]	26,565		[14,477]

Number of prescriptions orders		3,847 [2,122]			3,808		[1,859]

% ≥ 70 new AD		0.86		[0.34]	0.95		[0.20]

Number of DDD		9,163		[6298]	14,848		[8,200]

AD prescription ratio		0.30		[0.09]	0.60		[0.27]


	Total group (n = 1,304)	No sexual violence (n = 806)	Rape (n = 183)	Non-consensual sex (n = 315)	F/χ2

A	15	15.73 (1.		1	13.


Item		N	Time 1 (Pre)	Time 3 (6 Month)	Mean change*	P value*

			Mean	SD	Mean	SD	Mean	95% CI

1	I am confident that I have the interview skills to use my time well with suicidal clients.	59	51.69	21.60	68.83	16.33	17.14	12.88 – 21.39	0.000

2	After seeing a client once I would be confident that I could recognise potential suicide risk.	59	37.44	21.33	58.05	20.07	20.61	14.96 – 26.26	0.000

3	I feel confident that I could differentiate a mild depression from a suicide risk.	59	49.95	23.14	68.37	16.20	18.42	13.29 – 23.56	0.000

4	I am confident in dealing with the needs of suicidal clients.	59	42.75	21.95	65.98	17.16	23.24	18.53 – 27.95	0.000

	Total	59	181.83	74.59	261.24	61.20	79.41	63.55 – 95.26	0.000

Item		N	Time 1 (Pre)	Time 3 (6 Month)	Mean change*	P value*

			Mean	SD	Mean	SD	Mean	95% CI

2	After seeing a client once I would be confident that I could recognise potential suicide risk.	59	37.44	21.33	58.05	20.07	20.61	14.96 – 26.26	0.000

3	I feel confident that I could differentiate a mild depression from a suicide risk.	59	49.95	23.14	68.37	16.20	18.42	13.29 – 23.56	0.000

4	I am confident in dealing with the needs of suicidal clients.	59	42.75	21.95	65.98	17.16	23.24	18.53 – 27.95	0.000

	Total	59	181.83	74.59	261.24	61.20	79.41	63.55 – 95.26	0.000


Author, year	Study population (period)	Definition of HDP-related SAMM	Case fatality rate (Number of deaths/cases)	Mortality reductiona

				Natural case fatality

				25%	42%

Mantel et al, 1998[73]	Kalafong and Pretoria hospitals, South Africa (1996-1998)	Hypertension with organ failure	20.8% (10/48)	16.7%	50.4%

Khosla et al 2000[74]	One hospital, Rohtak, India (1998)	Eclampsia	17.7% (11/62)	29.0%	57.8%

Pattinson et al, 2003[75]	Three regions, South Africa (year not stated)	Hypertension with organ failure	20.7% (30/145)	17.2%	50.7%

Kaye et al 2003[76]	Mulago hospital, Uganda (2000)	Eclampsia/pre-eclampsia with organ failure	14.3% (3/21)	42.9%	66.0%

Oladapo et al 2007[77]	Olabisi Onabanjo hospital, southwest Nigeria (2002-2004)	Eclampsia and severe pre-eclampsia with clinical/laboratory indications for termination of pregnancy to save the woman's live	14.9% (21/141)	40.4%	64.5%

Adisasmita et al 2008[78]	Four hospitals in West-Java, Indonesia (2003-2004)	Eclampsia and pre-eclampsia with organ failure	3.9% (22/563)	84.4%	90.7%

Roost et al 2009[79]	Four public hospitals in La Paz and El Alto, Bolivia (2006-2007)	Eclampsia and pre-eclampsia based on clinical and management criteria	0.5% (1/184)	98.0%	98.8%

Author, year	Study population (period)	Definition of HDP-related SAMM	Case fatality rate (Number of deaths/cases)	Mortality reductiona

				Natural case fatality

				25%	42%

Mantel et al, 1998[73]	Kalafong and Pretoria hospitals, South Africa (1996-1998)	Hypertension with organ failure	20.8% (10/48)	16.7%	50.4%

Khosla et al 2000[74]	One hospital, Rohtak, India (1998)	Eclampsia	17.7% (11/62)	29.0%	57.8%

Pattinson et al, 2003[75]	Three regions, South Africa (year not stated)	Hypertension with organ failure	20.7% (30/145)	17.2%	50.7%

Kaye et al 2003[76]	Mulago hospital, Uganda (2000)	Eclampsia/pre-eclampsia with organ failure	14.3% (3/21)	42.9%	66.0%

Oladapo et al 2007[77]	Olabisi Onabanjo hospital, southwest Nigeria (2002-2004)	Eclampsia and severe pre-eclampsia with clinical/laboratory indications for termination of pregnancy to save the woman's live	14.9% (21/141)	40.4%	64.5%

Adisasmita et a	Four hos	Eclampsia and pre-eclampsia with organ	3.9% (	84.	9

l 2008[78]	pitals in West-Java, Indonesia (2003-2004)	 failure	22/563)	4%	0.7%

Roost et al 2009[79]	Four public hospitals in La Paz and El Alto, Bolivia (2006-2007)	Eclampsia and pre-eclampsia based on clinical and management criteria	0.5% (1/184)	98.0%	98.8%


Characteristic	Number of patients(%)

Sex

Female	318 (29.1)

Male	775 (70.9)

Age (years)

Median

(range)	47 (15-90)

≤ 47	568

> 47	517

Missing	8

Follow-up time (months)

Median	67 (1-120)

(range)

Clinical stage

I-II	315 (29.0)

III-IV	773 (71.0)

Missing	5

Relapse

No	1001 (91.7)

Yes	91 (8.3)

Missing	1

Metastasis

No	984 (90.1)

Yes	108 (9.9)

Missing	1

Therapeutic modality

Radiotherapy	766 (70.6)

Chemotherapy	10 (0.9)

Radiochemotherapy	309 (28.5)

Missing	8

WHO histological classification

NKUC	853 (78.3)

NKDC	206 (18.9)

KSCC	30 (2.8)

Missing	4

OS rate (%)

5-year	69.1


Group	Quintile	Total PA	Moderate PA	Vigorous PA	MVPA

		OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI


Parameter	Benign (n = 102)	Malignant (n = 11)	P value

Age	58.9 ± 16.4	48.8 ± 18.7	0.059

Female gender	66 (64.7)	5 (45.5)	0.209

Urgent intervention	22 (21.6)	10 (90.9)	<0.01

Coronary artery disease	8 (7.8)	0 (0.0)	0.335

Valvular heart disease	12 (11.8)	0 (0.0)	0.229

Congenital heart disease	0 (0.0)	1 (9.1)	0.742

Thromboembolic disease	3 (2.9)	0 (0.0)	0.564


Hospital	Case (male/female)	Percentage of total

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine	178 (111/67)	5.03%

Guanganmen Hospital affiliated to China Academy of Chinese Medical Science	564 (363/201)	15.95%

Huairou Hospital of Traditional Chinese Medicine	121 (77/44)	3.42%

Beijing Hospital of Traditional Chinese Medicine	220 (142/78)	6.22%

People's Hospital affiliated to Beijing University	107 (72/35)	3.03%

Tongzhou Hospital of Traditional Chinese Medicine	160 (98/62)	4.52%

Tongren Hospital affiliated to Capital University of Medical Sciences	260 (162/98)	7.35%

Wangjing Hospital affiliated to China Academy of Chinese Medical Science	93 (58/35)	2.63%

Xiyuan Hospital affiliated to China Academy of Chinese Medical Science	462 (304/158)	13.06%

China-Japan Friendship Hospital	632 (425/207)	17.87%

Beijing Hospital of Integrated Traditional Chinese with Western Medicine	124 (80/44)	3.51%

Anzhen Hospital affiliated to Capital University of Medical Sciences	616 (422/194)	17.42%

Hospital	Case (male/female)	Percentage of total

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine	178 (111/67)	5.03%

Guanganmen Hospital affiliated to China Academy of Chinese Medical Science	564 (363/201)	15.95%

Huairou Hospital of Traditional Chinese Medicine	121 (77/44)	3.42%

Beijing Hospital of Traditional Chinese Medicine	220 (142/78)	6.22%

People's Hospital affiliated to Beijing University	107 (72/35)	3.03%

Tongzhou Hospital of Traditional Chinese Medicine	160 (98/62)	4.52%

Tongren Hospital affiliated to Ca	260 (162/98	7.35

Hospital	Case (male/female)	Percentage of total

pital University of Medical Sciences	)	%

Wangjing Hospital affiliated to China Academy of Chinese Medical Science	93 (58/35)	2.63%

Xiyuan Hospital affiliated to China Academy of Chinese Medical Science	462 (304/158)	13.06%

China-Japan Friendship Hospital	632 (425/207)	17.87%

Beijing Hospital of Integrated Traditional Chinese with Western Medicine	124 (80/44)	3.51%

Anzhen Hospital affiliated to Capital University of Medical Sciences	616 (422/194)	17.42%


Cluster of Life Sciences	BMBS - Biomedicine and Molecular BiosciencesFA - Food and AgricultureFPS - Forests, their Products and Services

Cluster of Natural Sciences	CMST - Chemistry and Molecular Sciences and TechnologiesESSEM - Earth System Science and Environmental ManagementMPNS - Materials, Physical and Nanosciences

Cluster of Science and Society	ISCH - Individuals, Societies, Cultures and HealthICT - Information and Communication TechnologiesTUD - Transport and Urban Development

Trans Domain area (not a separate Domain currently) – allows for multidisciplinary proposals which cannot be submitted to a single Domain.

Cluster of Life Sciences

Cluster of Natural Sciences

Cluster of Science and Society

Trans Domain area (not a separate Domain currently) – allows for multidisciplinary proposals which cannot be submitted to a single Domain.

BMBS - Biomedicine and Molecular BiosciencesFA - Food and AgricultureFPS - Forests, their Products and Services

CMST - Chemistry and Molecular Sciences and TechnologiesESSEM - Earth System Science and Environmental ManagementMPNS - Materials, Physical and Nanosciences

ISCH - Individuals, Societies, Cultures and HealthICT - Information and Communication TechnologiesTUD - Transport and Urban Development

Trans Domain area (not a separate Domain currently) – allows for multidisciplinary proposals which cannot be submitted to a single Domain.


Chronic Disease (outcome variables)	Frequent mental distress (FMD) Beta (SE)1	Obesity Beta (SE)1

Diabetes	0.55 (0.03)2	1.17 (0.02)2

High Blood Pressure	0.54 (0.02)2	0.99 (0.02)2

Coronary Heart Disease	0.90 (0.04)2	0.41 (0.03)2

Strok	0.93 (0	0.18 (0.04)

Chronic Disease (outcome variables)	Frequent mental distress (FMD) Beta (SE)1	Obesity Beta (SE)1

e	.04)2	2

Asthma	0.62 (0.03)2	0.42 (0.02)2

Arthritis	0.87 (0.02)2	0.61 (0.02)2


Factor	Factor level	Frequency (n)	Percentage	Chi-square	df	Significance

Habitat stability	Permanent	214	63.13

	Temporary	125	36.87	22.317	1	0.000

Habitat origin	Man-made	326	96.17

	Natural	13	3.83	0.873	1	0.350

Water origin	Surface run-off	279	82.30

	Underground	60	17.70	5.254	1	0.022

Habitat size	<10	45	13.27

	>100	50	14.75

	10 - 100	244	71.98	9.822	2	0.007

Water movement	No	301	88.79

	Yes	38	11.21	0.768	1	0.381

Vegetation	Absent	149	43.95

	Present	190	56.05	11.547	1	0.001


Haplotype	Freq (case)	Freq (control)	P	OR (95% CI)


Demographic characteristics	Value

Age in years, mean (range)	55.9 (42 to 79)

Race, n (%)

White	4 (50)

African heritage	2 (25)

Asian - Japanese/East Asian/Southeast Asian heritage	1 (13)

Asian - Central/South Asian heritage	1 (13)

Baseline ECOG performance status, n (%)

0	6 (77)

2	2 (25)

Time since diagnosis (years), median (range)	4.5 (1 to 9)

Demographic characteristics

Age in years, mean (range)

Race, n (%)

White

African heritage

Asian - Japanese/East Asian/Southeast Asian heritage

Asian - Central/South Asian heritage

Baseline ECOG performance status, n (%)

0

2

Time since diagnosis (years), median (range)


Trial	Hb (g/L)	Ferritin (μg/L)	TSAT (%)	BM iron

Auerbach 2004 [26]	≤105	≤200	≤19*	 ND

Auerbach 2010 [31]	≤100	≥10	≥15	 ND

Bastit et al. [29]	<110	10–800	≥15	 ND

Hedenus et al. [28]	90–110	<800	—	 +

Henry et al. [27]	<110	100–900	15–35	 ND

Pedrazzoli et al. [30]	<110	100–800	20–40	 ND

Steensma et al. [32]	<110	≥20	<60	 ND


	Healthy volunteers	ObT2D	HV/ObT2D

(n = 19)	(n = 20)	p value

Intra-myocardium dixon fat fraction (%)	7.9 ± 3.7	6.0 ± 1.5

Dixon 3D epicardial fat volume (mL)	176.4 ± 68.6	273.8 ± 64.0	***

Indexed dixon 3D epicardial fat volume (mL/m2)	89.7 ± 25.2	123.6 ± 23.4	***

Dixon 3D epicardial fat fraction (%)	21.0 ± 4.0	28.4 ± 5.5	***

	Healthy volunteers	ObT2D	HV/ObT2D

(n = 19)	(n = 20)	p value

Indexed dixon 3D epicardial fat volume (mL/m2)	89.7 ± 25.2	123.6 ± 23.4	***

Dixon 3D epicardial fat fraction (%)	21.0 ± 4.0	28.4 ± 5.5	***


Name	Chr	Binsa	QTL confidence interval, bp	LODb	R2	Additive Effectc

Left border	Right border

QTLGLSchr8	8	8.02-8.04	14,069,105	118,971,618	22.83246	0.265049	105.1474


Stage 1: selection of study sites

Region	Country	Estimated no. ART clinics (yr. of assessment)	Estimated no. adult ART enrollees at ART clinics	No. eligible clinics*	Estimated no. study-eligible adult ART enrollees at eligible clinics	Site sampling technique	No. clinics selected

Southern Africa	Mozambique	379 (2014)	582,000	254	446,379	Census	254

Namibia	213 (2014)	165,468	213	165,468	Census	213

Swaziland	31 (2009)	50,767	31	50,767	PPS	16

Zimbabwe	104 (2008)	103,806	70	93,811	PPS	40

Zambia	322 (2007)	65,383	129	58,845	Purposive	6

East Africa	Tanzania	210 (2007)	41,920	85	37,728	Purposive	6

Uganda	286 (2007)	45,946	114	41,351	Purposive	6

West Africa	Nigeria††	178 (2009)	168,335	139	167,438	PPS	35

Caribbean	Haiti	200 (2015)	65,000	191	60,705	Census	191

Southeast Asia	Vietnam	173 (2009)	28,090	120	25,000	PPS	30

Total	—	2,096	1,316,715	1,346	1,147,492	—	797

Stage 2: selection of study patients

Region	Country	Age-eligibility criteria (age at ART initiation) (yrs)	ART enrollment years covered by analysis	Patient sampling technique at selected clinics	Planned sample size*	No. eligible medical recordsanalyzed	Date of data collection

Southern Africa	Mozambique	≥15	2004–2013	Census	446,379	446,379	Dec 2014

Namibia	≥15	2004–2012	Census	165,468	165,468	Dec 2013

Swaziland	≥15	2004–2010	SRS	2,500	2,510	Nov 2011–Feb 2012

Zimbabwe	≥15	2007–2009	SRS	4,000	3,896†	Jan–Jun 2010

Zambia	≥18	2004–2009	SRS	1,500	1,214§	Apr–Jul 2010

East Africa	Tanzania	≥18	2004–2009	SRS	1,500	1,421¶	Apr–Jul 2010

Uganda	≥18	2004–2009	SRS	1,500	1,466**	Apr–Jul 2010

West Africa	Nigeria††	≥15	2004–2011	SRS	3,500	3,496	Dec 2012–Aug 2013

Caribbean	Haiti	≥15	2004–2015	Census	60,705	60,705	Jun 2016

Southeast Asia	Vietnam	≥15	2005–2009	SRS	7,587	7,583§§	Jan–Jun 2010

Total	—	—	—	—	694,639	694,138	—

Stage 1: selection of study sites

Region	Country

Southern Africa	Mozambique

Namibia

Swaziland

Zimbabwe

Zambia

East Africa	Tanzania

Uganda

West Africa	Nigeria††

Caribbean	Haiti

Southeast Asia	Vietnam

Total	—

Stage 2: selection of study patients

Region	Country

Southern Africa	Mozambique

Namibia

Swaziland

Zimbabwe

Zambia

East Africa	Tanzania

Uganda

West Africa	Nigeria††

Caribbean	Haiti

Southeast Asia	Vietnam

Total	—

Stage 1: selection of study sites

Estimated no. ART clinics (yr. of assessment)	Estimated no. adult ART enrollees at ART clinics	No. eligible clinics*	Estimated no. study-eligible adult ART enrollees at eligible clinics	Site sampling technique	No. clinics selected

379 (2014)	582,000	254	446,379	Census	254

213 (2014)	165,468	213	165,468	Census	213

31 (2009)	50,767	31	50,767	PPS	16

104 (2008)	103,806	70	93,811	PPS	40

322 (2007)	65,383	129	58,845	Purposive	6

210 (2007)	41,920	85	37,728	Purposive	6

286 (2007)	45,946	114	41,351	Purposive	6

178 (2009)	168,335	139	167,438	PPS	35

200 (2015)	65,000	191	60,705	Census	191

173 (2009)	28,090	120	25,000	PPS	30

2,096	1,316,715	1,346	1,147,492	—	797

Stage 2: selection of study patients

Age-eligibility criteria (age at ART initiation) (yrs)	ART enrollment years covered by analysis	Patient sampling technique at selected clinics	Planned sample size*	No. eligible medical recordsanalyzed	Date of data collection

≥15	2004–2013	Census	446,379	446,379	Dec 2014

≥15	2004–2012	Census	165,468	165,468	Dec 2013

≥15	2004–2010	SRS	2,500	2,510	Nov 2011–Feb 2012

≥15	2007–2009	SRS	4,000	3,896†	Jan–Jun 2010

≥18	2004–2009	SRS	1,500	1,214§	Apr–Jul 2010

≥18	2004–2009	SRS	1,500	1,421¶	Apr–Jul 2010

≥18	2004–2009	SRS	1,500	1,466**	Apr–Jul 2010

≥15	2004–2011	SRS	3,500	3,496	Dec 2012–Aug 2013

≥15	2004–2015	Census	60,705	60,705	Jun 2016

≥15	2005–2009	SRS	7,587	7,583§§	Jan–Jun 2010

—	—	—	694,639	694,138	—


CT technique description	Injection activity (MBq)	Effective dose (mSv)	Effective dose per unit activity (mSv/MBq)

	Male	Female	Male	Female	Male	Female

Standard CT	455 ± 30	450 ± 26	8.1 ± 1.2	10.1 ± 1.4	0.018 ± 0.002	0.022 ± 0.002

Diagnostic CT	455 ± 25	454 ± 51	8.1 ± 0.8	9.9 ± 1.6	0.018 ± 0.002	0.022 ± 0.003

CT technique description	Injection activity (MBq)	Effective dose (mSv)	Effective dose per unit activity (mSv/MBq)

	Male	Female	Male	Female	Male

Standard CT	455 ± 30	450 ± 26	8.1 ± 1.2	10.1 ± 1.4	0.018 ± 0.002

Diagnostic CT	455 ± 25	454 ± 51	8.1 ± 0.8	9.9 ± 1.6	0.018 ± 0.002

Effective dose per unit activity (mSv/MBq)

Female

0.022 ± 0.002

0.022 ± 0.003


Gene Ontologya	DAVIDb

Biological process

 Cell adhesion (GO:0007155)	0.0000148

 Cell communication	0.000632

G-protein signaling, coupled to cyclic nucleotide second messenger	0.001940c

 System development (GO:0048731)	0.000000016

Central nervous system development	0.000293c

 Organ development (GO:0048513)	0.000017

Cellular compartment

 Integral to membrane (GO:0016021)	0.0000018

 Integral to plasma membrane (GO:0005887)	0.000000026

 Dystrophin-associated glycoprotein complex	0.002081c

Sarcoglycan complex	0.004398c

Molecular function

 Signal transducer activity (GO:0004871)	0.0000025

 Transmembrane receptor activity (GO:0004888)	0.0000274

Transmembrane receptor protein phosphatase activity	0.003811c

Amine receptor activity	0.004557c

Hematopoietin/interferon-class (D200-domain) cytokine receptor activity	0.001526c

 Phosphoinositide binding	0.000737c

GPI anchor binding	0.003257c

 Calcium-release channel activity	0.004102c

 Delayed rectifier potassium channel activity	0.001212c

Enriched KEGG pathways	PEb

 Cell adhesion molecules (CAMs)	0.00000036

 Neuroactive ligand-receptor interaction	0.000542

 Allograft rejection	0.001545

 Type I diabetes mellitus	0.003487


Outcome and instrument	Method	Data collection time

T0	T1	T2

Perceived health

SF-36	Interview caregiver or mailed questionnaire	x	x	x

Objective burden

Short version iBMG	Interview caregiver or mailed questionnaire	x	x	x

instrument objective burden informal care

Subjective burden

Carer-Qol	Interview caregiver or mailed questionnaire	x	x	x

SRB	Interview caregiver or mailed questionnaire	x	x	x

CSI+	Interview caregiver or mailed questionnaire	x	 	x

Perseverance time	Interview caregiver or mailed questionnaire	x	 	x

ASIS	Interview caregiver or mailed questionnaire	x	 	x

Quality of life

SF-36	Interview caregiver or mailed questionnaire	x	x	x

Cantril’s self-anchoring ladder	Interview caregiver or mailed questionnaire	x	x	x

Use of community services

Self-reported	Interview caregiver or mailed questionnaire	x	x	x

CSAI	Interview caregiver or mailed questionnaire	x	 	x

Outcome and instrument

Perceived health

SF-36

Objective burden

Short version iBMG

instrument objective burden informal care

Subjective burden

Carer-Qol

SRB

CSI+

Perseverance time

ASIS

Quality of life

SF-36

Cantril’s self-anchoring ladder

Use of community services

Self-reported

CSAI

Method	Data collection time

T0	T1	T2

Interview caregiver or mailed questionnaire	x	x	x

Interview caregiver or mailed questionnaire	x	x	x

Interview caregiver or mailed questionnaire	x	x	x

Interview caregiver or mailed questionnaire	x	x	x

Interview caregiver or mailed questionnaire	x		x

Interview caregiver or mailed questionnaire	x		x

Interview caregiver or mailed questionnaire	x		x

Interview caregiver or mailed questionnaire	x	x	x

Interview caregiver or mailed questionnaire	x	x	x

Interview caregiver or mailed questionnaire	x	x	x

Interview caregiver or mailed questionnaire	x		x


Strategy	Treatment	Genomic Profile	Phase	N	ORR (%)	PFS (M)	OS (M)	Clinical Development	Reference

BRAF monotherapy	Vemurafenib	BRAFmut	I/II	21	5	2.1	7.7	Complete	NCT00405587 [93]

BRAF monotherapy	Vemurafenib	BRAFmut	II	10	0	4.5	9.3	Complete	NCT01524978 [94]

BRAF + MEK	Dabrafenib + Trametinib	BRAFmut	I/II	43	12	3.5	(−)	Complete	NCT01726738 [88]

BRAF + EGFR	Vemurafenib + Cetuximab	BRAFmut	II	27	4	3.7	7.1	Complete	NCT01524978 [94]

BRAF + EGFR	Vemurafenib + Panitumumab	BRAFmut	Pilot	15	13	3.2	7.6	Complete	NCT01791309 [89]

BRAF + EGFR	Encorafenib + Cetuximab	BRAFmut	II	50	22	4.2	12.4	Ongoing	NCT01719380 [90]

BRAF + EGFR	Dabrafenib + Panitumumab	BRAFmut	I/II	20	10	3.4	(−)	Ongoing	NCT01750918 [85]

BRAF + EGFR	BMS-908662 + Cetuximab	Kras mut or BRAF mut	I/II	17 *	(−)	(−)	(−)	Ongoing	NCT01086267

BRAF + EGFR + CT	Vemurafenib + Cetuximab + irinotecan	BRAFmut	I	12	50	(−)	(−)	Ongoing	NCT01787500

BRAF + EGFR + CT	Cetuximab + irinotecan ± Vemurafenib	BRAFmut	II (RCT)	78 *	(−)	(−)	(−)	Ongoing	NCT02164916

BRAF + EGFR + MEK	Dabrafenib + Panitumumab + Trametinib	BRAFmut	I/II	83	18	(−)	(−)	Ongoing	NCT01750918 [85]

BRAF + EGFR ± MEK	Encorafenib + Cetuximab ± Binimetinib	None	III	645 *	(−)	(−)	(−)	Ongoing	NCT02928224

BRAF + EGFR + PI3K	Encorafenib + Cetuximab + Alpelisib	BRAFmut	II	52	27	5.4	13.1	Ongoing	NCT01719380 [90]

MEK + CT	Selumetinib + irinotecan	Kras mut or BRAF mut	II	32	9	(−)	(−)	Complete	NCT01116271 [95]

MEK + EGFR	Binimetinib + Panitumumab	RAS wt or RAS mut	I/II	90 *	(−)	(−)	(−)	Ongoing	NCT01927341

MEK + EGFR	Panitumumab + Trametinib	BRAFmut	I/II	31	0	2.8		Ongoing	NCT01750918 [85]

MEK + EGFR	Trametinib + Panitumumab	KRAS BRAF wt	II	26 *	(−)	(−)	(−)	Ongoing	NCT02399943

MET + EGFR + CT	Cetuximab + irinotecan ± Tivantinib	KRAS wt	I/II (RCT)	60	45	8.3	19.8	Complete	NCT01075048 [96]

MEK + AKT	Selumetinib + MK-2206	KRAS wt or KRAS mut	II	21 *	(−)	(−)	(−)	Ongoing	NCT01333475

Strategy	Treatment	Genomic Profile	Phase	N	ORR (%)	PFS (M)	OS (M)	Clinical Development	Reference

MET + EGFR + CT	Cetuximab + irinotecan ± Tivantinib	KRAS wt	I/II (RCT)	60	45	8.3	19.8	Complete	NCT01075048 [96]

MEK + AKT	Selumetinib + MK-2206	KRAS wt or KRAS mut	II	21 *	(−)	(−)	(−)	Ongoing	NCT01333475


Dose level	N	Radiation therapy dose (Gy)	Dose delay due to AE

Level 1	3	62	62a	64	1 (3 days)

Level 2	6	64	60	62	0

	64	62	60

Level 3	6	60	64	62	1 (7 days)

	64	60b	62

Dose level	N	Radiation therapy dose (Gy)	Dose delay due to AE

Level 1	3	62	62a	64	1 (3 days)

Level 2	6	64	60	62	0

	64	62	60

Level 3				6	1

Dose level	N	Radiation therapy dose (Gy)	Dose delay due to AE

	6	60	64	2	 (7 days)

	64	60b	62


Socio -demographic Characteristic	Number	%

Age (in years)

 15–34	109	25.6

 25–34	166	39.1

 35–44	150	35.3

Ethnicity

 Sinhalese	256	60.2

 Tamils	83	19.5

 Muslims	80	18.9

 Burgher & others	6	1.4

Religion

 Buddhism	244	57.4

 Hindu	72	16.9

 Islam	78	18.4

 Christianity	31	7.3

Current marital Status

 Currently Married	286	67.3

 Never Married	98	23.1

 Widowed	24	5.6

 Divorced/ Separated	17	4.0

Highest level of Education

 Never went to school	48	11.3

 Primary education	197	46.3

 Secondary education or higher	180	42.4

Daily family income (in USD)

 Less than 2.4 USD (poor income)	73	17.2

 2.5–12 USD (low income)	348	81.9

 More than 12 USD (middle income)	4	0.9

Employment status

 Employed	224	52.7

 Unemployed	201	47.3

Employment Category (n = 224)

 Professionals	14	6.3

 Clerical and sales workers	34	15.1

 Elementary occupations	113	50.5

 Others	63	28.1

Social status

 High social status	106	24.9

 Low social status	319	75.1


IR score	A II(n = 6)	A III(n = 12)	GBM (n = 55 )	Control cortex/autopsy (n = 8)	Control cortex/surgical (n = 5)

Kir4.1	3.6 ± 0.85*	7.18 ± 0.41	5.5 ± 0.30	7.13 ± 0.36	7.03 ± 0.26


Category	Characteristic	Comparison	Pre-campaign	Mid-campaign	Post-campaign

Household health behaviour	Child reported to have had measles vaccine	Yes vs. no	1.12 (0.75, 1.67)	0.87 (0.28, 2.86)	5.67 (2.68, 11.99)

Child’s birthplace	Healthcare facility vs. home	1.34 (1.03, 1.72)	1.34 (0.52, 3.46)	0.47 (0.22, 0.97)


Assay		Primer Sequence 5’-3’

<underline>Pyrosequencing</underline>

Assay 1 (20 CpGs)	Forward	GGATGTGGGGATTTTTTTTTTTTAGTATAG

	Reverse	Biotin-ACTTCAACCCCTCCCCCAAAA

	Sequencing 	TTTTTTAGTATAGTAAAGTTGGT

Assay 2 (12 CpGs) 	Forward	TTTCGGGTTTTATAGTTTTTGTATTTAGGT

	Reverse	Biotin-ACTCCCGCAACTCAATAAACTCAAACTC

	Sequencing 	TTTAGTAGTTTAGTTTGGATTTTGG

MOAP1 	Forward	GAGTGTTAGTTAGAGTTTAGGGGAGTTT

	Reverse	Biotin-CTCACCCCTCCCAACCCT

	Sequencing 	AGGGGAGTTTGTTTT

<underline>qRT-PCR</underline>

GAPDH 	Forward	CATGACAACTTTGGTATCGTG

	Reverse	GTGTCGCTGTTGAAGTCAGA

RASSF1a	Forward	CCTCTGTGGCGACTTCATCTG

	Reverse	CAACAGTCCAGGCAGACGAG

MOAP-1	Forward	CTCAATTGCTCCTCTCTGTACC

	Reverse	CATGACAACTTTGGTATCGTG

RASSF1c	Forward	GCTACTGCAGCCAAGAGGAC

	Reverse	AGGTGTCTCCCACTCCACAG

PPIA	Forward	GCCGAGGAAAACCGTGTACT

	Reverse	TGTCTGCAAACAGCTCAAAGG

Assay		Primer Sequence 5’-3’

Pyrosequencing

Assay 1 (20 CpGs)	Forward	GGATGTGGGGATTTTTTTTTTTTAGTATAG

	Reverse	Biotin-ACTTCAACCCCTCCCCCAAAA

	Sequencing	TTTTTTAGTATAGTAAAGTTGGT

Assay 2 (12 CpGs)	Forward	TTTCGGGTTTTATAGTTTTTGTATTTAGGT

	Reverse	Biotin-ACTCCCGCAACTCAATAAACTCAAACTC

	Sequencing	TTTAGTAGTTTAGTTTGGATTTTGG

MOAP1	Forward	GAGTGTTAGTTAGAGTTTAGGGGAGTTT

	Reverse	Biotin-CTCACCCCTCCCAACCCT

	Sequencing	AGGGGAGTTTGTTTT

qRT-PCR


Riparian metric	Mean annual rainfall	Mean annual temperature	Bank height	Proportion of clay

Estimate	SE	Estimate	SE	Estimate	SE	Estimate	SE

SPECIES RICHNESS	0.0347***	0.009	0.0238**	0.0085	−0.0178	0.009

ABUNDANCE	12.933**	3.824

NATIVE REGEN	13.904***	3.314	6.708**	3.824

BASAL AREA	0.631*	0.299

SPECIES RICHNESS NS	0.047***	0.012

NATIVE REGEN NS	10.207*	4.020

BASAL AREA NS							0.199**	0.068

Riparian metric	Mean annual rainfall	Mean annual temperature

Estimate	SE	Estimate

SPECIES RICHNESS	0.0347***	0.009	0.0238**

ABUNDANCE	12.933**	3.824

NATIVE REGEN	13.904***	3.314	6.708**

BASAL AREA	0.631*	0.299

SPECIES RICHNESS NS	0.047***	0.012

NATIVE REGEN NS	10.207*	4.020

BASAL AREA NS

Mean annual temperature	Bank height	Proportion of clay

SE	Estimate	SE	Estimate	SE

0.0085	−0.0178	0.009

3.824

			0.199**	0.068


 	O. scapulalis	O. nubilalis

Raw short sequence number	322,504	307,622

Number after filtering	287,429	272,490

Mean read length (bp)	352	356

Number of singletons	85,070	87,110

Number of assembled reads	145,588	130,897

Assembled transcriptome (Mbp)	10.35	9.52

Reads/bp	9.8	10.2

Number of unigenes	8,892	8,656

Number of transcripts (including alternative transcripts)	11,231	10,773

Transcript mean length (bp)	922	883

Transcript median length (bp)	693	685

Transcript N50 length (bp)	1,036	991

Mean exon count per transcript	1.54	1.49

Mean exon* length (bp)	604	605

Median exon length (bp)	500	495

	O. scapulalis	O. nubilalis

Transcript mean length (bp)	922	883

Transcript median length (bp)	693	685

Transcript N50 length (bp)	1,036	991

Mean exon count per transcript	1.54	1.49

Mean exon* length (bp)	604	605

Median exon length (bp)	500	495


Study [reference]: countries	Population	n	Efficacy	Lower bound of 95% CI	Adherencea

Partners PrEP [8]: Kenya, Uganda	Heterosexual couples	4758	67% TDF; 75% TDF/FTC	44% TDF; 55% TDF/FTC	82%

TDF2 Study [9]: Botswana	Young men and women	1219	62% TDF/FTC	21.5%	80%

Bangkok TDF [12]: Thailand	IVDU	2413	49% TDF	9.6%	67%

iPrEx [7]: S. America, SA, Thailand, USA	MSM	2499	44% TDF/FTC	15%	51%

FEM-PrEP [10]: Kenya, SA, Tanzania	Young women	2120	6% TDF/FTC	−52%	37%

VOICE [11]: South Africa, Uganda, Zimbabwe	Young women	5029	−49% TDF; - 4% TDF/FTC	−130% TDF; −50% TDF/FTC	30%

Study [reference]: countries	Population	n

Partners PrEP [8]: Kenya, Uganda	Heterosexual couples	4758

TDF2 Study [9]: Botswana	Young men and women	1219

Bangkok TDF [12]: Thailand	IVDU	2413

iPrEx [7]: S. America, SA, Thailand, USA	MSM	2499

FEM-PrEP [10]: Kenya, SA, Tanzania	Young women	2120

VOICE [11]: South Africa, Uganda, Zimbabwe	Young women	5029

Efficacy	Lower bound of 95% CI	Adherencea

67% TDF; 75% TDF/FTC	44% TDF; 55% TDF/FTC	82%

62% TDF/FTC	21.5%	80%

49% TDF	9.6%	67%

44% TDF/FTC	15%	51%

6% TDF/FTC	−52%	37%

−49% TDF; - 4% TDF/FTC	−130% TDF; −50% TDF/FTC	30%


Risk factor	Crude OR	Adjusted ORa

Participant’s father’s T2D	1.77 (1.37–2.28)	1.37 (1.03–1.83)


	PANSS positive subscale score	PANSS negative subscale score	PANSS general psychopathology subscale score	PANSS total score

Serum S100B level changes	r=0.3P=0.2	r=-0.048P=0.8	r=0.05P=0.8	r=0.06P=0.7

Leptin (microg/ml)	r=-0.3P=0.1	r=-0.023P=0.9	r=-0.2P=0.2	r=-0.3P=0.1

	PANSS positive subscale score	PANSS negative subscale score	PANSS general psychopathology subscale score	PANSS total score

Serum S100B level	r=0.3P	r=-0.048P=	r=0.05P=	r=0.06


	Run 1	Run 2	Summary

HRM	n	%	n	%	n	%

 Number of samples	120	100.0	20	100.0 (16.7)	120	100.0

 Analysis passed	89	74.2	18	90.0	105	87.5

WT (total)	60	67.4	12	66.7	71	67.6

WT (skewed HRM curve)	3	5.0	2	16.7	4	5.6

Mutant (total)	29	32.6	6	33.3	34	32.4

Mutant (skewed HRM curve)	1	3.4	1	16.7	1	2.9

 Analysis failed	31	25.8	2	10.0

Pyrosequencing	n	%	n	%	n	%

 Number of samples	19	100.0 (15.8)	3	100.0 (2.5)	19	100.0

 Analysis passed	18	94.7	2	66.7	18	94.7

WT	12	66.7	0	0.0	13	72.2

Potential low level mutation	2	11.1	1	50.0	0	0.0

Mutant	4	22.2	1	50.0	5	27.8

 Analysis failed	1	5.3	1	33.3	1

Combined HRM + Pyrosequencing					n	%

 Number of samples					120	100.0

 Number of HRM runs					140	116.7

 Number of pyrosequencing runs					22	18.3

 Analysis passed					119	99.2

 WT					81	68.1

 Mutant					38	31.9

 Analysis failed					1	0.8

	Run 1	Run 2	Summary

Mutant	4	22.2	1	50.0	5	27.8

Analysis failed	1	5.3	1	33.3	1

Combined HRM + Pyrosequencing					n	%

Number of samples					120	100.0

Number of HRM runs					140	116.7

Number of pyrosequencing runs					22	18.3

Analysis passed					119	99.2

WT					81	68.1

Mutant					38	31.9

Analysis failed					1	0.8


URL structure	Get	Post	Delete

/namespace/object_type/	List objects, apply filters	Create new object or make bulk update	Bulk delete

/namespace/object_type/id/	Access single object	Update single object	Delete single object

/namespace/object_type/id/acl/	Get object permissions	Update object permissions	405 Not Supported

structure	t	t	Delete

/namespace/object_type/	List objects, apply filters	Create new object or make bulk update	Bulk delete

/namespace/object_type/id/	Access single object	Update single object	Delete single object

/namespace/object_type/id/acl/	Get object permissions	Update object permissions	405 Not Supported


		Gender

Female	Male	Total

Need for treatment

 Discussed and confirmeda	17	36	53

 Discussed, not confirmed	0	0	0

 Not mentioned	1	0	1

Danger to self

 Discussed and confirmed	2	2	4

 Discussed, not confirmed	2	5	7

 Not mentioned	14	29	43

Danger to others

 Discussed and confirmed	0	3	3

 Discussed, not confirmed	3	2	5

 Not mentioned	15	31	46

Voluntary care unrealistic

 Discussed and confirmed	5	5	10

 Discussed, not confirmed	0	2	2

 Not mentioned	13	29	42

Substance abuse

 Discussed and confirmed	0	8	8

 Discussed, not confirmed	6	10	16

 Not mentioned	12	18	30


RTI/STI symptomatic currently or within last 3 months	n = 353	%

Sought care for RTI/STI symptoms

 Yes		238	67.4

 No		115	32.6

Time delay until seeking care (days)	(n = 238)

 Mean: 10.2	(range: 2-60)

 < 7		137	57.6

 7-14		55	23.1

 > 15		46	19.3

Source of RTI/STI treatment the last time	(n = 238)

 Drop-in centre		126	52.9

 Public hospital		56	23.5

 Private clinic		29	12.2

 Pharmacy/drugstore		22	9.2

 Herbalist		5	2.1

RTI/STI symptomatic currently or within last 3 months	n = 353	%

Time delay until seeking care (days)	(n = 238)

Mean: 10.2	(range: 2-60)

< 7		137	57.6

7-14		55	23.1

> 15		46	19.3

Source of RTI/STI treatment the last time	(n = 238)

Drop-in centre		126	52.9

Public hospital		56	23.5

Private clinic		29	12.2

Pharmacy/drugstore		22	9.2

Herbalist		5	2.1


 	LBD alone (n = 62)	EST plus LBD (n = 69)	P value

Diameter of inflated balloon (mm)	15.9 ± 2.3 (12-20)	16.2 ± 2.5 (12-20)	0.444

Complete stone removal irrespective of whether ML was used, no. (%)	60 (96.8)	66 (95.7)	0.738

Complete stone removal without ML, no. (%)	50 (80.6)	51 (73.9)	0.360

	LBD alone (n = 62)	EST plus LBD (n = 69)	P value

Complete stone removal without ML, no. (%)	50 (80.6)	51 (73.9)	0.360


Disease class	Nt	Nur	FIC

Gastrointestinal	17	145	0.88

Respiratory	5	15	0.71

Wound healing	2	3	0.50

Dermatological	1	2	1.00

Kidney problems	2	4	0.66

Blood diseases	4	10	0.66

Cardiovascular	1	3	1.00

Inflammations	1	1	1.00

Hepatic problems	2	5	0.75

General pain	3	6	0.60

Fever	1	3	1.00

Dental	1	3	1.00

Disease class	Nt	Nur

Gastrointestinal	17	145

Respiratory	5	15

Wound healing	2	3

Dermatological	1	2

Kidney problems	2	4

Blood diseases	4	10

Cardiovascular	1	3

Inflammations	1	1

Hepatic problems	2	5

General pain	3	6

Fever	1	3

Dental	1	3


Phenotype	n	CaseAverageRelatedness	MeanControlAverageRelatedness	Empiricalp-valueGIF	Empiricalp-valueDistantGIF

CFS	811	3.15	2.31	< 0.001	0.010


 	 	 	Normal PI	Low PI

Restricted growth parameters	Subclass of SGA	N	no (%)	no (%)

Weight, length and OFC	Symmetrical	1	1 (100.0)	0 (0.0)

Weight and length alone	Symmetrical	25	23 (92.0)	2 (8.0)

Weight alone	Asymmetrical	33	20 (60.6)	13 (39.4)

Restricted growth parameters	Subclass of SGA

Weight, length and OFC	Symmetrical

Weight and length alone	Symmetrical

Weight alone	Asymmetrical


Amino acid substituted in Y114	37 °C	65 °Ca

Isomerase activity (mM/min μg)	Epimerase activity (mM/min μg)	Isomerase activity (mM/min μg)	Epimerase activity (mM/min μg)

Y (parent)	15.6 ± 1.2	138 ± 2.3	187 ± 4.2	37.0 ± 3.6

V	9.74 ± 1.4	nd	29.2 ± 3.3	nd

N	5.84 ± 0.71	nd	9.73 ± 2.2	nd

S	1.95 ± 0.39	nd	17.5 ± 4.0	nd

A	9.74 ± 2.0	nd	25.3 ± 3.2	nd

K	9.74 ± 0.98	nd	15.6 ± 2.1	nd

G	3.90 ± 1.3	nd	15.6 ± 2.2	nd

D	11.7 ± 1.9	nd	17.5 ± 2.1	nd

C	5.84 ± 1.0	nd	15.6 ± 1.9	nd

L	nd	nd	29.2 ± 2.6	nd

E	17.5 ± 2.3	nd	208 ± 3.9	11.7 ± 2.2

Amino acid substituted in Y114	37 °C	65 °Ca

Isomerase activity (mM/min μg)	Epimerase activity (mM/min μg)	Isomerase activity (mM/min μg)	Epimerase activity (mM/min μg)

P	1.95 ± 0.55	nd	17.5 ± 1.2	nd

I	7.79 ± 1.9	nd	17.5 ± 1.1	nd

W	nd	nd	11.7 ± 1.2	nd

T	3.90 ± 0.2	nd	7.81 ± 2.1	nd

R	nd	nd	13.6 ± 1.0	nd

F	1.95 ± 0.13	9.74 ± 2.1	48.7 ± 3.2	9.77 ± 3.2

M	3.90 ± 0.22	nd	17.5 ± 2.9	nd

Q	1.92 ± 0.08	nd	23.4 ± 3.4	nd

H	nd	nd	15.6 ± 2.8	nd


References	Primary outcomes	Secondary outcomes

Song (weak)1[44]	Recalled stocking and sales scores were higher in intervention stores than in control stores.	There was improvement in some specific mediator factors but not in overall mediator factors.

Gittelsohn 2010b (weak) [42]		No changes were shown in most mediator factors between intervention and control stores.

Ayala 2013 (moderate)2[29]	The intervention increased availability of vegetables but not fruit.	Self-efficacy for consuming more fruits decreased.


	Tree 1	Tree 2	Tree 3	Pfam

Average sequence identity	19%	30%	42%	-

Alignment length	1080	629	597	404

Sequence length	173	177	169	171

Original number of sequences	32	33	46	-

Average number of sequences after MaxAlign	14.1	22.6	28.8	-

Average number of indels per sequence	66.6	54.3	48.5	32

Average length of indels	13.6	8.3	8.8	7


Compounds	KB b	A549 b	Compounds	KB b	A549 b

Etoposid	0.85 ±	0.99 	C	2.45 ± 0.41	5.2


Baseline	Pre App	App	Post App

Complete DASS-21	Rate subjective wellbeing and distress daily for 7 days	Rate subjective wellbeing and distress daily for 7 days	Complete DASS-21

	Complete DASS-21 after 7 days	Record answers to MOL-style questions received as text messages	Attend short, semi-structured interview to describe the experience of receiving and answering questions


Parameter	Value

Maximum data rate	250 kbps

Discovery packet time	10 s

Transmission power	0 dBm

Receiver sensitivity	−85 dBm

Average frame length	22 Bytes

MAC layer	CSMA/CA

Maximum number of backoffs	4

Packet loss	1%

Coverage radio	50 m

Mode	Active

Jamming	Reactive

Scenario	Static

Area	150 m × 150 m

Parameter	Value

Average frame length	22 Bytes

MAC layer	CSMA/CA

Maximum number of backoffs	4

Packet loss	1%

Coverage radio	50 m

Mode	Active

Jamming	Reactive

Scenario	Static

Area	150 m × 150 m


Primers and probes	Gene sequence

GAPDH sense	TGCACCACCAACTGCTTAG

GAPDH antisense	GGATGCAGGGATGATGTTC

GAPDH probe	CAGAAGACTGTGGATGGCCCCTC

IL-1β sense	TCCTGAACTCAACTGTGAAATGC

IL-1β antisense	AGCCCAGGTCAAAGGTTTGG

IL-1β probe	AGCAGCCCTTCATCTTTTGGGGTCCG

IL-6 sense	CCGGAGAGGAGACTTCACAGA

IL-6 antisense	GTTGTTCATACAATCAGAATTGCCATT

IL-6 probe	ACCACTCCCAACAGACCTGTCTATACCACT

CCL2 sense	TCTGGGCCTGCTGTTCACA

CCL2 antisense	CCAGCCTACTCATTGGGATCA

CCL2 probe	TTGGCTCAGCCAGATGCAGTTAACGC

CCL3 sense	ATTCCACGCCAATTCATCGT

CCL3 antisense	TTGGAGTCAGCGCAGATCTG

CCL3 probe	CCTTTGCTCCCAGCCAGGTGTCATT

Primers and probes	Gene sequence

IL-1β sense	TCCTGAACTCAACTGTGAAATGC

IL-1β antisense	AGCCCAGGTCAAAGGTTTGG

IL-1β probe	AGCAGCCCTTCATCTTTTGGGGTCCG

IL-6 sense	CCGGAGAGGAGACTTCACAGA

IL-6 antisense	GTTGTTCATACAATCAGAATTGCCATT

IL-6 probe	ACCACTCCCAACAGACCTGTCTATACCACT

CCL2 sense	TCTGGGCCTGCTGTTCACA

CCL2 antisense	CCAGCCTACTCATTGGGATCA

CCL2 probe	TTGGCTCAGCCAGATGCAGTTAACGC

CCL3 sense	ATTCCACGCCAATTCATCGT

CCL3 antisense	TTGGAGTCAGCGCAGATCTG

CCL3 probe	CCTTTGCTCCCAGCCAGGTGTCATT


		Baseline	Reexamination

	N	27	25

	Mean dmft ± SD	5.1 ± 1.8	8.8 ± 0.7

ECC stages	Initial stage (N, %)	(27) 100%	(0) 0%

	Circular stage (N, %)	/	(7) 28%

	Destructive stage (N, %)	/	(5) 20%

	Radix relicta stage (N, %)	/	(9) 36%

	Extraction (N, %)	/	(4) 16%


Characteristic

Total population

Metro area segregation

0.13<Dm<0.40 (97 CBSAs)

0.40≤Dm<0.50 (105 CBSAs)

0.50≤Dm<0.60 (78 CBSAs)

0.60≤Dm<0.76 (24 CBSAs)

Race/ethnicity

Hispanic

Non-Hispanic

Asian

Black

White

Housing tenure

Rented housing unit

Owner occupied

Household income relative to poverty

Below poverty

Near poverty

At least twice poverty level

aTotal of 81,517,417 individuals in 63,436 block groups in 304 metropolitan areas.


Number (%) of 	Pre-eclamptic (N = 143)	Controls(N = 143)	P

Primigravidae	49(34.3)	27(18.9)	0.01

lack of antenatal care	21(14.7)	33(23.1)	0.02

Educational level < secondary	36(25.2)	24(16.8)	0.8

Bednets coverage	21(14.7)	23 (16.1)	0.6

History of malaria	31(21.7)	11(7.7)	0.001

Family history of hypertension	122(85.3)	81(56.6)	0.001

Placental malaria	28(19.6)	16(11.2)	0.04


Test	Cutoff for “abnormal”	All Stages (N = 5731)	Stage 1 (N = 4058)	Stage 2 (N = 981)	Stage 3 (N = 692)

Urine Tests

Eosinophils	≥1 %	6.9	5.8	7.2	7.5

Total Protein	>15 mg/dl	70.8	63.0	64.3	83.3

UPEP	M spike	7.9	5.0	9.8	10.0

Blood Tests

ANCA	Titer > 1:20	10.6	8.0	3.7	14.9

Anti-GBM	≥1.0	0	0	0	0

Cryoglobulin	>0 %	21.8	26.3	0	21.2

C3	<90 mg/dl	36.5	26.9	21.1	45.6

C4	<10 mg/dl	12.9	11.6	10.5	14.3

Free Light Chains	See below	41.6	44.7	42.9	36.7

SPEP	M spike	19.1	16.4	23.9	19.7

Radiology Tests

Renal Ultrasound	See Methods	34.6	40.6	23.4	34.9

CT Abdomen/Pelvis	See Methods	33.3	26.7	27.3	39.3

Test	Cutoff for “abnormal”	All Stages (N = 5731)	Stage 1 (N = 4058)	Stage 2 (N = 981)	Stage 3 (N = 692)

Renal Ultrasound	See Methods	34.6	40.6	23.4	34.9

CT Abdomen/Pelvis	See Methods	33.3	26.7	27.3	39.3


Variable	Median (25th, 75th percentile)

Sleep

 Time in bed (hours:minutes)	9:31 (9:02, 9:58)

 Sleep duration (hours:minutes)	8:29 (7:59, 8:59)

 Sleep midpoint (hours:minutes)	2:44 (2:14, 3:29)

 Sleep efficiency (%)	90.0 (86.3, 92.5)

Physical activity (minutes/day)

 Outdoor active play (minutes/day)	32.7 (15.8, 54.2)

 Organized sports (minutes/day)	18.8 (0.0, 48.6)

 Curriculum-based physical activity (minutes/day)	9.8 (2.1, 16.6)

 Active transportation (minutes/day)	12.2 (5.4, 21.3)


Pre-SBRT factors	G4-5 RP	G0-3 RP	Total	X2 test	1-year cumulative incidence of G4-5 RP	log-rank

Serum KL-6

high value	6	17	23	p = 0.0002	32%	p < 0.0001

within normal level	2	78	80		3%

not available	1	13	14

Serum SP-D

high value	5	14	19	p = 0.0002	29%	p = 0.0001

within normal level	2	79	81		3%

not available	2	15	17

IP shadow in CT

(+)	7	6	13	p < 0.0001	57%	p < 0.0001

(-)	2	102	104		2%

Pre-SBRT factors	G4-5 RP	G0-3 RP	Total	X2 test	1-year cumulative incidence of G4-5 RP	log-rank

(+)	7	6	13	p < 0.0001	57%	p < 0.0001

(-)	2	102	104		2%


	Cross-section 2004	Panel 2002–2004

Variable	Average for treated	Average for untreated	Single difference in averages	% difference	Boot-strapped Std. Err.	P-value	Double differences/differences-in-differences (absolute)

No. of outpatient (OP) visits in the 12-month recall period	0.818	0.786	0.033	4%	0.060	0.585	0.06

no. of OP visits at commune level clinics	0.380	0.308	0.072	23%	0.034	0.034	0.10

no. of OP visits at district hospital	0.144	0.078	0.066	85%	0.022	0.003	Not available

no. of OP visits at provincial/central hospital	0.051	0.029	0.022	74%	0.009	0.018	Not available

no. of OP visits at govt. hospital	0.195	0.107	0.088	82%	0.025	0.000	0.08

no. of OP visits at private facility	0.222	0.357	-0.135	-38%	0.039	0.000	-0.12

No. of inpatient (IP) admissions in the 12-month recall period	0.125	0.118	0.007	6%	0.012	0.557	0.00

no. of IP admissions at commune level clinics	0.026	0.037	-0.010	-28%	0.004	0.020	0.00

no. of IP admissions at district hospital	0.060	0.038	0.023	60%	0.008	0.003	Not available

no. of IP admissions at provincial/central hospital	0.035	0.038	-0.002	-6%	0.006	0.721	Not available

no. of IP admissions at govt. hospital	0.096	0.075	0.021	27%	0.011	0.065	0.02


Acupuncture and Moxibustion	11(1.4)	---	11(2.4)

Therapeutic Massage	40(5.1)	---	40(8.9)

Qigong	75(9.5)	---	75(16.7)

Chinese Dietary Therapy


Strain of C. jejuni	Rate of growth (μmax) in microaerobic conditions	Death times (D-values) in aerobic conditions

Bf	0.5763	\**

subsp. jejuni NCTC 11168	0.7714*	0.9737

subsp. jejuni 00-2538	0.9198*	1.1039

subsp. jejuni 00-2426	0.8964*	1.5442

subsp. jejuni 00-2544	0.8303*	1.4554

subsp. jejuni 00-2425	0.9085*	1.3785

subsp. jejuni 81-176	0.9477*	0.4765

subsp. jejuni NCTC 11828	0.7899*	1.3417

subsp. doylei 269.97	0.7765*	2.2691

subsp. jejuni RM 1221	0.6793*	1.9276

Strain of C. jejuni	Rate of growth (μmax) in microaerobic conditions	Death times (D-values) in aerobic conditions

subsp. jejuni NCTC 11168	0.7714*	0.9737

subsp. jejuni 00-2538	0.9198*	1.1039

subsp. jejuni 00-2426	0.8964*	1.5442

subsp. jejuni 00-2544	0.8303*	1.4554

subsp. jejuni 00-2425	0.9085*	1.3785

subsp. jejuni 81-176	0.9477*	0.4765

subsp. jejuni NCTC 11828	0.7899*	1.3417

subsp. doylei 269.97	0.7765*	2.2691

subsp. jejuni RM 1221	0.6793*	1.9276


Quality-of-care categorya	Summary score

Baseline	End of the study

Intervention group, mean (SD)	Control group, mean (SD)	Intervention versus control group, mean difference (95% CI)	Intervention group, mean (SD)	Control group, mean (SD)	Intervention versus control group, mean difference (95% CI)

Hospital support systems


Level of Adaptation to Heat	% Who Reported Adverse Health Impacts	Confidence Interval	Coeff. of Variation	Odds Ratio	Confidence Interval	Pr > χ2

Individuals who adapt well	45.77	(41.78–49.76)	4.44	1.37	(1.13–1.66)	0.0011

Individuals who do not adapt as well 	38.11	(33.66–42.56)	5.95	1.00

Level of Adaptation to Heat	% Who Reported Adverse Health Impacts	Confidence Interval	Coeff. of Variation	Odds Ratio	Confidence Interval	Pr > χ2

Indiv		(41.7			(1.1	0.


	Kidney	Kidney pancreas

Number recruited	42	19

Sex male/female	31M/11F	9M/10F

Median age (range)	54 (26–74)	47 (30–59)

Donor type

Living (male/female)	16 (11M/5F)	n/a

DBD (male/female)	11 (7M/4F)	16 (7M/9F)

DCD (male/female)	15 (13M/ F)	3 (2M/1F)

Drug treatment regimen

Alemtuzumab	19	19

Basiliximab + MMF	13	n/a

Basiliximab + Aza	10	n/a

	Kidney	Kidney pancreas

Donor type

Living (male/female)	16 (11M/5F)	n/a

DBD (male/female)	11 (7M/4F)	16 (7M/9F)

DCD (male/female)	15 (13M/ F)	3 (2M/1F)

Drug treatment regimen

Alemtuzumab	19	19

Basiliximab + MMF	13	n/a

Basiliximab + Aza	10	n/a


Demographic	Physicians (n = 13)	Nursing staff (n = 13)	Overall (n = 26)

Sex	Male	4	1	5

Female	9	12	21

Age (yr)	Mean (range)	45 (25–60)	45 (24–61)	45 (24–61)

Years of professional experience	Mean (range)	15 (0–36)	17 (0–32)	16 (0–36)

Type of facility	Nursing home	10	9	19

Residential care home	3	4	7

Facility location	Urban area	8	7	15

Rural area	5	6	11

Professional specialism	Nursing home	Elderly care physician (7)	Nurse* (4)	-

Elderly care physician in training (1)

Junior doctor (1)	Nurse assistant* (5)

Physician assistant (1)

Residential care home	General practitioner (3)	Nurse assistant* (4)

Sex	Female	9	12	21

Age (yr)	Mean (range)	45 (25–60)	45 (24–61)	45 (24–61)

Years of professional experience	Mean (range)	15 (0–36)	17 (0–32)	16 (0–36)

Type of facility	Nursing home	10	9	19

Residential care home	3	4	7

Facility location	Urban area	8	7	15

Rural area	5	6	11

Professional specialism	Nursing home	Elderly care physician (7)	Nurse* (4)	-

Elderly care physician in training (1)

Junior doctor (1)	Nurse assistant* (5)

Physician assistant (1)

Residential care home	General practitioner (3)	Nurse assistant* (4)


Year	Main Objetive	Assay Employed	Reference

In vitro studies

2014	Effect of MGN on gamma radiation-induced DNA damage in human lymphocytes and lymphoblastoid cells.	Comet assay	[74]

2012	Evaluation of protective effects of MGN against several mutagens (bleomycin, CP, AFB1, B[a]P, 2-AAF, H2O2, sodium azide, cisplatin, MMC, and DMNA).	Ames test, SOS Chromotest assay & Comet assay	[75]

2009	Cytoprotective and antigenotoxic potential of mangiferine against cadmium chloride CdCl2-induced toxicity in HepG2 cells.	Comet assay & Micronucleus	[76]

2011	Evaluation of the protector effect of MGN against methylmercury (MeHg) induced neurotoxicity by employing IMR-32 (human neuroblastoma) cell line.	Comet assay & Micronucleus	[77]

2011	Antigenotoxic potential of MGN against mercuric chloride (HgCl2)-induced genotoxicity in HepG2 cell line.	Comet assay & Micronucleus	[78]

2015	Evaluation of the Mangiferin to reduce etoposide-induced DNA damage in human umbilical cord mononuclear blood cells.	Comet assay & Micronucleus	[79]

In vivo studies

2008	Protective role of mangiferin against B[a]P induced lung carcinogenesis in experimental animals.	Comet assay	[80]

2005	Ability of the mangiferin to reduce the frequency of radiation-induced micronucleated binucleate cells (MNBNCs) in cultured human peripheral blood lymphocytes.	Micronucleus	[81]

2010	The protective role of mangiferin (MGN) against cadmium chloride CdCl2-induced genotoxicity studied in Swiss albino mice.	Micronucleus	[82]

Year	Main Objetive	Assay Employed	Reference

2011	Evaluation of the protector effect of MGN against methylmercury (MeHg) induced neurotoxicity by employing IMR-32 (human neuroblastoma) cell line.	Comet assay & Micronucleus	[77]

2011	Antigenotoxic potential of MGN against mercuric chloride (HgCl2)-induced genotoxicity in HepG2 cell line.	Comet assay & Micronucleus	[78]

2015	Evaluation of the Mangiferin to reduce etoposide-induced DNA damage in human umbilical cord mononuclear blood cells.	Comet assay & Micronucleus	[79]

In vivo studies

2008	Protective role of mangiferin against B[a]P induced lung carcinogenesis in experimental animals.	Comet assay	[80]

2005	Ability of the mangiferin to reduce the frequency of radiation-induced micronucleated binucleate cells (MNBNCs) in cultured human peripheral blood lymphocytes.	Micronucleus	[81]

2010	The protective role of mangiferin (MGN) against cadmium chloride CdCl2-induced genotoxicity studied in Swiss albino mice.	Micronucleus	[82]


	RMSE

EKF	BD-AEKF

Heading (degree)	1.0069	0.3751

Pitch (degree)	0.6812	0.1453

Roll (degree)	0.6488	0.1466

East position (m)	0.8297	0.2050

North position (m)	0.8104	0.2194


Ownership	n(%)

Household owning nets	638(95.2)

Households without nets	32(4.8)

Total	670(100)

No. of bed nets	No. of HH(%)

0	32(4.8)

1	120(17.9)

2	244(36.4)

3	147(21.9)

4	88(13.1)

5+	39(5.8)

Total	670(100)

Mean number of nets per HH 2.4

Source of bed nets	No. of HH(%)

Campaign nets	298(46.7)

Non campaign nets	205(32.1)

Campaign &non campaign nets	112(17.6)

*Other sources	23(3.6)

Total	638(100)

Cost of non-campaign nets (KES)

50	180(56.8)

100	64(20.2)

> 100	73(23.0)

Total HH	317(100)

Ownership

Household owning nets

Households without nets

Total

No. of bed nets

0

1

2

3

4

5+

Total

Mean number of nets per HH 2.4

Source of bed nets

Campaign nets

Non campaign nets

Campaign &non campaign nets

*Other sources

Total

Cost of non-campaign nets (KES)

50

100

> 100

Total HH


Rank	Symptoms	Rate of patients with the symptom	Rate of patients with high PeCDF (> 50 pg/g lipids)

1	Black comedones (trunk) <+ or severer>	0.0671	0.6563

2	uric acid (high)	0.1761	0.6310*

3	Black comedones (face) <+ or severer>	0.0860	0.6098

4	Third quartile age	0.2348	0.6071*

5	urea nitrogen (high)	0.1111	0.6038

6	red blood cell count (low)	0.1342	0.5938

7	History of pigmentation <present>	0.3669	0.5886*

8	Classification of testee <qualified>	0.7526	0.5794*

9	Subjective symptoms, etc. <present>	0.1488	0.5775

10	Second quartile age	0.2788	0.5714


Item	IntraobserverObserver 1	IntraobserverObserver 2	InterobserverOver assessments 1

ICC	Agreement (in %)	95% CI	ICC	Agreement (in %)	95% CI	ICC	Agreement (in %)	95% CI


Protocol	Denaturation	Touchdown annealing cycles	Additional annealing cycles	Extension	Final extension

GP5+/GP6+	1 min, 94°C	-	2 min, 40°C (40–50 cycles)	1.5 min, 72°C	4 min, 72°C

TDP1	1 min, 94°C	2 min, 45°C to 40°C in 0.5°C decrements (11 cycles)	2 min, 40°C (29–39 cycles)	1.5 min, 72°C	4 min, 72°C

TDP2	1 min, 94°C	2 min, 50°C to 40°C in 1.0°C decrements (11 cycles)	2 min, 40°C (29–39 cycles)	1.5 min, 72°C	4 min, 72°C

TDP3	1 min, 94°C	2 min, 50°C to 40°C in 0.5°C decrements (21 cycles)	2 min, 40°C (19–29 cycles)	1.5 min, 72°C	4 min, 72°C

TDP4	1 min, 94°C	2 min, 55°C to 40°C in 1.0°C decrements (16 cycles)	2 min, 40°C (24–34 cycles)	1.5 min, 72°C	4 min, 72°C

Protocol	Denaturation	Touchdown annealing cycles	Additional annealing cycles	Extension	Final extension

TDP1	1 min, 94°C	2 min, 45°C to 40°C in 0.5°C decrements (11 cycles)	2 min, 40°C (29–39 cycles)	1.5 min, 72°C	4 min, 72°C

TDP2	1 min, 94°C	2 min, 50°C to 40°C in 1.0°C decrements (11 cycles)	2 min, 40°C (29–39 cycles)	1.5 min, 72°C	4 min, 72°C

TDP3	1 min, 94°C	2 min, 50°C to 40°C in 0.5°C decrements (21 cycles)	2 min, 40°C (19–29 cycles)	1.5 min, 72°C	4 min, 72°C

TDP4	1 min, 94°C	2 min, 55°C to 40°C in 1.0°C decrements (16 cycles)	2 min, 40°C (24–34 cycles)	1.5 min, 72°C	4 min, 72°C


Characteristic	HR	95% CI

Male sex	1.39	1.06–1.81

Age, per 10-year increment	1.09	1.07–1.10

Smoking	1.34	1.03–1.76

Drinking	1.03	0.81–1.31

Obesity	0.96	0.75–1.23

Hypertension	2.65	2.11–3.31

Dyslipidemia	1.08	0.87–1.35

Diabetes mellitus	2.07	1.40–3.06

AF	4.11	2.28–7.41

Characteristic

Male sex

Age, per 10-year increment

Smoking

Drinking

Obesity

Hypertension

Dyslipidemia

Diabetes mellitus

AF


Time (h)	pNO2PheDUa (mM)	Conversion (%)

0


	t0 control	t0 inoculated	t1 control	t1 inoculated	t2 control	t2 inoculated

Resistance to antibiotics and toxic compounds	80.7	81.4	78.9	78.8	79.7	79.8

–	9.7	9.1	10.3	10.2	10.4	10.2

Multi locus sequence typing	7.2	7.2	8.2	8.4	7.5	7.4

Adhesion	1.4	1.4	1.5	1.5	1.5	1.5

Bacteriocins, ribosomally synthesized antibacterial peptides	0.4	0.5	0.6	0.5	0.4	0.6

Invasion and intracellular resistance	0.4	0.3	0.3	0.3	0.3	0.3

Toxins and superantigens	0.1	0.1	0.2	0.2	0.2	0.1

Resistance to antibiotics and toxic compounds

–

Multi locus sequence typing

Adhesion

Bacteriocins, ribosomally synthesized antibacterial peptides

Invasion and intracellular resistance

Toxins and superantigens


Baseline Characteristics (at time of diagnosis)	Mean ± SD or N (%)

Age (Years)	37.41 ± 10.14

Gender

 Male	14 (66.7%)

 Female	07 (33.3%)

Stage of Disease

 I	3 (14.3%)

 II	2 (9.5%)

 III	4 (19.0%)

 IV	12 (57.1%)

LDH

 High	18 (85.7%)

 Normal	03 (14.3%)

Extra Nodal site involvement

 None	5 (23.8%)

 Yes	16 (76.2%)

Bulky Disease

 Yes	5 (23.8%)

 No	16 (76.2%)

Bone Marrow Involvement

 Yes	8 (38.1%)

 No	13 (61.9%)

IPI

 1	04 (19.0%)

 2	09 (42.9%)

 3	08 (38.1%)


Variables	N	%

Gender	Male	29	58

Female	21	42

Educational level	Basic science (pre-clinical) years	12	24

Clinical years	38	76

Previous EBM exposure	Read about or attended a lecture	28	56

Had a formal EBM training	0	 0

Previous research exposure	Participated in ≥ 1 research activity	31	62

No previous research exposure	19	38

Frequency of online search for evidence	≥ once per week	16	32

< once per week, or not at all	34	68

First source sought for evidence (before the course)	Google	23	46

UpToDateTM	13	26

PubMed	7	14

The Cochrane library	1	 2

Other	3	 6

Variables	N	%

Gender	Male	29	58

Female	21	42

Educational level	Basic science (pre-clinical) years	12	24

Clinical years	38	76

Previous EBM exposure	Read about or attended a lecture	28	56

Had a formal EBM training	0	0

Previous r	Participa	31	62

esearch exposure	ted in ≥ 1 research activity

No previous research exposure	19	38

Frequency of online search for evidence	≥ once per week	16	32

< once per week, or not at all	34	68

First source sought for evidence (before the course)	Google	23	46

UpToDateTM	13	26

PubMed	7	14

The Cochrane library	1	2

Other	3	6


Characteristics	Patients (P, n=131)	Spousal caregivers (SC, n=131)

	n (%)	n (%)

Age (mean± SD), years	56.6±12.1 (ranging from 25 to 79)	56.0±11.3 (ranging from 29 to 80)

Gender

 Male	82 (62.6)	49 (37.4)

 Female	49 (37.4)	82 (62.6)

Level of education

 Primary school or less	64 (48.9)	67 (51.1)

 High school	49 (37.4)	49 (37.4)

 University or above	18 (13.7)	15 (11.5)

Working status

 Working	75 (57.3)	69 (52.7)

 Not working	56 (42.7)	62 (47.3)

The average time since diagnosis/the duration in their role as a SC	13.7±23.0 months (ranging from 1 to 192 months)	<6 months:	67 (51.2)

6 months ~2 years:	43 (32.8)

>2 years ~5 years:	13 (9.9)

>5 years:	8 (6.1)

Couples were informed about the diseaseb

 Partly informed	33 (25.2)	24 (18.3)

 Well informed	98 (74.8)	107 (81.7)

Time spent by SC in caring for patients/day [in hours, n (%)]		<2 hours:	10 (7.6)

2~4 hours:	14 (10.7)

>4~6 hours:	25 (19.1)

>6~8 hours:	21 (16.0)

>8 hours:	61 (46.6)

Types of cancera	Digestive system cancer: 72 (55.0); Lung cancer: 35 (26.7);

	Urogenital system cancer: 19 (14.5); Others: 5 (3.8)

Dyad Characteristicsc

Duration of marriage (mean± SD), years	30.8±11.6 (ranging from 1–52)

Relationship with their partner before the diagnosis of the cancer	Very goodBad	115 (87.8)0	Normal	16 (12.2)

Change in the relationship with their partner after the diagnosis of the cancer	ImprovedGetting worse	38 (29.0)0	No change	93 (71.0)

Financial burden on the family due to the treatment of cancer	Serious	77 (58.8)	Normal	49 (37.4)

	Mild or None	5 (3.8)

Characteristics	Patients (P, n=131)	Spousal caregivers (SC, n=131)

	n (%)	n (%)

Age (mean± SD), years	56.6±12.1 (ranging from 25 to 79)	56.0±11.3 (ranging from 29 to 80)

Gender

Male	82 (62.6)	49 (37.4)

Female	49 (37.4)	82 (62.6)

Level of education

Primary school or less	64 (48.9)	67 (51.1)

High school	49 (37.4)	49 (37.4)

University or above	18 (13.7)	15 (11.5)

Working status

Working	75 (57.3)	69 (52.7)

Not working	56 (42.7)	62 (47.3)

The average time since diagnosis/the duration in their role as a SC	13.7±23.0 months (ranging from 1 to 192 months)	<6 months:

6 months ~2 years:

>2 years ~5 years:

>5 years:

Couples were informed about the diseaseb

Partly informed	33 (25.2)	24 (18.3)

Well informed	98 (74.8)	107 (81.7)

Time spent by SC in caring for patients/day [in hours, n (%)]		<2 hours:

2~4 hours:

>4~6 hours:

>6~8 hours:

>8 hours:

Types of cancera	Digestive system cancer: 72 (55.0); Lung cancer: 35 (26.7);

	Urogenital system cancer: 19 (14.5); Others: 5 (3.8)

Dyad Characteristicsc

Duration of marriage (mean± SD), years	30.8±11.6 (ranging from 1–52)

Relationship with their partner before the diagnosis of the cancer	Very goodBad	115 (87.8)0

Change in the relationship with their partner after the diagnosis of the cancer	ImprovedGetting worse	38 (29.0)0

Financial burden on the family due to the treatment of cancer	Serious	77 (58.8)

	Mild or None	5 (3.8)

Spousal caregivers (SC, n=131)

n (%)

56.0±11.3 (ranging from 29 to 80)

Gender

Level of education

Working status

67 (51.2)

43 (32.8)

13 (9.9)

8 (6.1)

Couples were informed about the diseaseb

24 (18.3)

107 (81.7)

10 (7.6)

14 (10.7)

25 (19.1)

21 (16.0)

61 (46.6)

Digestive system cancer: 72 (55.0); Lung cancer: 35 (26.7);

Urogenital system cancer: 19 (14.5); Others: 5 (3.8)

30.8±11.6 (ranging from 1–52)

Normal	16 (12.2)

No change	93 (71.0)

Normal	49 (37.4)


Characteristic	TeleWii Group (n = 38)	SIBT group (n = 38)	Baseline comparison p value


 	Johannesburg**	Cape town	Rustenburg

 	Surveys#	FGDs^	Diaries	Surveys#	FGDs*	Diaries	Surveys#	FGDs^	Diaries

Pre-World Cup	-	2	-	-	2	-	-	1	-

World Cup	350 (95%)	2	8	128 (77%)	2	7	123 (91%)	1	8

Post-World Cup	273 (98%)	1	16	83 (83%)	2	6	102 (88%)	1	8

	Johannesburg**	Cape town

	Surveys#	FGDs^	Diaries	Surveys#	FGDs*	Diaries

Pre-World Cup	-	2	-	-	2	-

World Cup	350 (95%)	2	8	128 (77%)	2	7

Post-World Cup	273 (98%)	1	16	83 (83%)	2	6

Rustenburg

Surveys#	FGDs^	Diaries

-	1	-

123 (91%)	1	8

102 (88%)	1	8


Severe disability	Any severe cerebral palsy (child non-ambulant and likely to remain so; GMFCS level 4 or 5), severe developmental delay (standardised score <−3 SD) or blindness.

Moderate disability	Moderate cerebral palsy (child non-ambulant at 2 years of age but who is likely to ambulate subsequently; GMFCS level 2 or 3), or deafness, or moderate developmental delay (standardised score from −3 SD to <−2 SD).

Mild disability	Mild cerebral palsy (child walking at 2 years of age with only minimal limitation of movement (GMFCS level 1), or suspect developmental delay (standardised score from −2 SD to <−1 SD).

No neurosensory disability	Children without any neurosensory impairment.

Severe disability	Any severe cerebral palsy (child non-ambulant and likely to remain so; GMFCS level 4 or 5), severe developmental delay (standardised score <−3 SD) or blindness.

Mod	Moderate cerebral palsy (child non-ambulant at 2 years of age but who is likely to ambulate subsequently; GMFCS level 2 or 3), or deafness, or moderate developmental delay (standardised score from −3 SD to <−2

erate disability	 SD).

Mild disability	Mild cerebral palsy (child walking at 2 years of age with only minimal limitation of movement (GMFCS level 1), or suspect developmental delay (standardised score from −2 SD to <−1 SD).

No neurosensory disability	Children without any neurosensory impairment.


What influences the decision about prenatal examinations?

n = 302	n (%)

Worry about the health of the baby	268 (89)

I want to know as much as possible	117 (39)

No reasons to refuse	81 (27)

Personal experience of chromosomal aberration or other severe disease among relative	69 (23)

The values of the society	44 (15)

Expectations from others	41 (14)

Everyone else does	14 (5)

Important to know the gender of the baby	4 (1)

Who influences the decision about prenatal examinations?

n = 302

My partner	250 (83)

The doctor in antenatal care	168 (56)

Family and friends	132 (44)

The midwife in antenatal care	129 (43)

No one, I make the decision myself	80 (26)

What influences the decision about prenatal examinations?

n = 302	n (%)

Worry about the health of the baby	268 (89)

I want to know as much as possible	117 (39)

No reasons to refuse	81 (27)

Personal experience of chromosomal aberration or other severe disease among relative	69 (23)

The values of the society	44 (15)

Expectations from others	41 (14)

Everyone else does	14 (5)

Important to know the	4

What influences the decision about prenatal examinations?

 gender of the baby	 (1)

Who influences the decision about prenatal examinations?

n = 302

My partner	250 (83)

The doctor in antenatal care	168 (56)

Family and friends	132 (44)

The midwife in antenatal care	129 (43)

No one, I make the decision myself	80 (26)


		Crude ORsab	95% CIc	p-value	Adjusted ORsd	95% CI	p-value

Age	≥30 years	(reference)			(reference)

	<30 years	3.43	1.96-5.99	< 0.001	2.74	1.36-5.50	0.005

Sex	Male	(reference)			(reference)

	Female	0.46	0.10-2.05	0.297	0.30	0.05-1.69	0.171

Mental health service	No	(reference)			(reference)

	Implemented	0.45	0.24-0.84	0.009	0.35	0.16-0.76	0.008

Key person	No	(reference)			(reference)

	Yes	0.80	0.45-1.41	0.438	0.58	0.28-1.19	0.135

Route of infection	Homosexual	(reference)

	Others	0.75	0.42-1.34	0.327

Regular employment	Yes	(reference)			(reference)

	No	2.46	1.38-4.39	0.002	3.38	1.58-7.23	0.002

Welfare benefits	No	(reference)

	Yes	0.43	0.05-3.48	0.414

HIV test motive	Voluntary	(reference)			(reference)

	Others	0.40	0.25-0.63	<0.001	1.50	0.38-2.70	0.180

Mental illness	No	(reference)

	Yes	0.92	0.31-2.77	0.886

Illicit drug use	No	(reference)

	Yes	1.25	0.67-2.33	0.492

Nationality	Japanese	(reference)

	Others	1.00	0.32-3.09	1.000

AIDS diagnosis	No	(reference)

	Yes	0.19	0.07-0.51	0.002

Antiretroviral therapy	Yes	(reference)			(reference)

	No	8.47	3.91-18.33	<0.001	7.51	3.34-16.9	< 0.001

CD4+ lymphocyte count	<200/mm3	(reference)

	200-499/mm3	3.94	1.35-11.5	0.012

	≥500/mm3	6.11	2.01-18.6	0.001


Vascular smooth muscle cells	Respiratory epithelial cells

Viability for different pressures (0, 0.4, 0.8, 1.2, 1.6, 2 bar)	Viability (0.4 bar)

Viability for different velocities (10, 30, 55, 75, 95 mL/min)	Short-term differentiation (pan-cytokeratin expression)

Short-term differentiation (α-SMA expression)	Long-term differentiation (14 and 28 days: pan-cytokeratin expression and PAS reaction)


p (FWEcorr)	T	Z	Coordinates x, y, z {mm} max. peak	Brain area

0.003843	7.936576	4.986516	18, 36, −8	Right medial orbitofrontal cortex


Economic interventions	Definition	Search terms

Price Interventions - Taxes and Subsidies	Interventions that target prices for goods and services paid/received by households or firms	“tax”, “subsidy”, “subsidized”, “subsidies”, “penalty”, “penalties”, “voucher”, “vouchers”

Income Transfer Programs	Interventions that transfer resources directly to households	“income support”, “financial supplement”, “income supplement”, “fina ncial assistance”, “welfare benefits”, “social security”, “cash assistance”, “income transfer”, “asset transfer”, “pensions”, “welfare payments”, “cash transfer”, “cash support”, “bonus”, “economic support”

Incentive Programs	Interventions that provide rewards or penalties to motivate specific behaviours/outcomes	“results-based financing”, “pay for performance”, “performance pay”, “performance incentives”, “financial incentives”, “activity based funding”, “provider payment”

Livelihood Support Programs	Interventions that provide resources or skills to support income generation	“livelihood support”, “entrepreneurship training”, “business training”, “vocational skills training”, “vocational training”

Health-related Financial Services	Interventions that provide mechanisms for managing resource allocations and financial risks.	“microcredit”, “microlending”, “microloans”, “microfinance”, “loans”, “lending”, “microinsurance”


Variables	Negative AV

Failure rate (%)	36.8

Surgical rate (%)	21.1

AV at PHV (°/y)	−9.6 ± 7.6

Initial curve magnitude (°)	26.3 ± 4.6

Final curve magnitude (°)	29.4 ± 9.1

PHV (cm/y)	8.8 ± 1.5

Timing of PHV (yrs)	11.7 ± 1.1

Age at diagnosis (yrs)	11.0 ± 1.3

Initial SSMS	2.7 ± 0.6

Initial DRU (R)	7.0 ± 0.8

Initial DRU (U)	5.1 ± 0.8

SSMS at PHV	3.4 ± 0.5

DRU (R) at PHV	8.0 ± 0.7

DRU (U) at PHV	5.9 ± 0.5

Percentage of major thoracic curve (%)	47.3

Initial height (cm)	145.2 ± 7.2

Final height (cm)	161.3 ± 5.4


 	Paucigranulocytic phenotype	Eosinophilic phenotype	Neutrophilic phenotype	Mixed granulocytic phenotype

Steroid naïve (n = 153)	65 (42.5%)	60 (39.2%)	25 (16.3%)	3 (2%)

Steroid-treated (n = 355)	138 (38%)	151 (43%)	55 (15%)	11 (3%)*

	Paucigranulocytic phenotype	Eosinophilic phenotype	Neutrophilic phenotype

Steroid naïve (n = 153)	65 (42.5%)	60 (39.2%)	25 (16.3%)

Steroid-treated (n = 355)	138 (38%)	151 (43%)	55 (15%)

Mixed granulocytic phenotype

3 (2%)

11 (3%)*


Level of Training	Teaching Method

M	C	A	E	SLE

Junior	Count	24	29	4	2	7

	% within TM	77.4	31.5	11.8	14.3	20

	Std Residual	4.5	−0.1	−2.1	−1.2	−1.3

Intermediate	Count	4	40	7	3	8

	% within TM	12.9	43.5	20.6	21.4	22.9

	Std Residual	−1.7	2.3	−1.0	−0.6	−0.8

Senior	Count	3	23	23	9	20

	% within TM	9.7	25	67.6	64.3	57.1

	Std Residual	−2.6	−2.0	2.8	1.6	1.9

Total		31	92	34	14	35


Sample No.	HN37	HN44	HN48

RL2	6a	9c	8b

RL3	11c	10b	9a

SL2	9a	12c	10b

SL3	12a	13b	12a

Sample No.	HN37	HN44	HN48

SL2	9a	12c	10b

SL3	12a	13b	12a


	Frequency

’NNP’,’DISEASE’,’NNP’	36

’NNP’,’NNP’,’DISEASE’,’NNP’	16

’NNP’,’DISEASE’,’NNP’,’NNP’	11

’IN’,’DISEASE’,’CC’	10

’NNP’,’DISEASE’,’NNP’

’NNP’,’NNP’,’DISEASE’,’NNP’

’NNP’,’DISEASE’,’NNP’,’NNP’

’IN’,’DISEASE’,’CC’


Lifetime diagnoses

16–24

25–34

35–44

45–54

55–64

65–74

Total aged 16–44

Total aged 45–74

Total

Past 5 years

16–24

25–34

35–44

45–54

55–64

65–74

Total aged 16–44

Total aged 45–74

Total


Ergonomic instructions	Health complaints often

	Eyes	Neck, shoulders	Head	Hands, fingers, wrists

	n*	OR (95%Cl)	N	OR (95%Cl)	N	OR (95%Cl)	n	OR (95%Cl)

To arrange desk, chair and screen in the right position	285	0.9 (0.7-1.1)	206	1.3 (1.0-1.7)	178	0.8 (0.7-1.1)	107	1.4 (0.9-2.1)

To take rest breaks	364	1.3 (1.0-1.6)	241	1.2 (0.9-1.6)	228	1.2 (0.9-1.6)	126	1.4 (0.9-2.0)

Health complaints often

Lower back

N	OR (95%Cl)

82	1.2 (0.8-1.9)

95	1.4 (0.9-2.3)


Characteristic	Total

Patients, N	448

HAE diagnosis, n (%)

 Type 1	423 (94.4)

 Type 2	25 (5.6)

Sex, n (%)

 Female	263 (58.7)

 Male	185 (41.3)

Age at enrollment, y

 Mean (SD)	40.8 (14.7)

 Median (min, max)	39.1 (16.5, 81.8)

Country, n (%)

 France	119 (26.6)

 Spain	69 (15.4)

 Germany	57 (12.7)

 United Kingdom	53 (11.8)

 Italy	46 (10.3)

 Israel	45 (10.0)

 Denmark	19 (4.2)

 Brazil	16 (3.6)

 Greece	14 (3.1)

 Austria	8 (1.8)

 Sweden	2 (0.4)


Client Characteristic	No. (%)

Sex

Female	1303 (91)

Male	122 (9)

Age, years

<15	75 (5)

15–18	786 (55)

19–20	514 (36)

21–24	50 (4)

No. of living children

0	757 (53)

1	502 (35)

2	148 (10)

3	14 (1)

5 or more	4 (0.3)

Marital status

Married or cohabiting	553 (39)

Single or living alone	872 (61)

First-time family planning user

Yes	987 (69)

No	438 (31)

Client Characteristic	No. (%)

2	148 (10)

3	14 (1)

5 or more	4 (0.3)

Marital status

Married or cohabiting	553 (39)

Single or living alone	872 (61)

First-time family planning user

Yes	987 (69)

No	438 (31)


Terms	aklB, ada	aklB, ada, dinJ

DNA repair (SP-PIR)	5.1E-28

DNA damage (SP-PIR)	6.2E-28

Cellular response to stress (GO)		7.5E-23

DNA repair (GO)		1.6E-21

Response to DNA damage stimulus (GO)		1.6E-21


Compounds	III Instar	Pupae

LC50	LC 90	Chi **	LC 50	LC 90	Chi **


AFL	AML	Stack	Description

signal S	-	(--)	Definition of a signal S.

: $S .. ;	DEF	(arg --)	Definition of a handler for signal S. The signal argument is pushed on the top of the data stack.

raise	RAISE	(arg sig# pid --)	Send a signal S with an argument to the process pid.

timer	TIMER	(sig# tmo --)	Install a timer (tmo > 0) raising signal sig if the time-out has passed. If tmo = 0, then the timer is removed.

AFL	AML	Stack	Description

raise	RAISE	(arg sig# pid --)	Send a signal S with an argument to the process pid.

timer	TIMER	(sig# tmo --)	Install a timer (tmo > 0) raising signal sig if the time-out has passed. If tmo = 0, then the timer is removed.


 	n	% who correctly identified the firstline anti-malarial therapy	Unadjusted odds ratio (95% confidence interval; P value)

Malaria training

Attended malaria workshop

 	Yes	46	65%	0.94 (0.42 - 2.07; 0.873)

 	No	66	67%	Ref

Attended malaria workshop after 2006

 	Yes	34	62%	0.32 (0.06 - 1.71; 0.184)

 	No	12	83%	Ref

Received drug information from MOH

 	Yes	94	69%	0.96 (0.85 - 1.08; 0.483)

 	No	19	53%	Ref

Dispensing Practices

Recommended AL for uncomplicated malaria in children under 5

 	Yes	43	74%	2.41 (1.01 - 5.76; 0.048)*

 	No	53	55%	Ref

Recommend AL for uncomplicated malaria in adults

 	Yes	55	76%	3.55 (1.49 - 8.47; 0.004)*

 	No	42	48%	Ref

Table 4b: Relationship between shop worker recommendation of AL to children under 5 and their response to clinical scenarios

 	 	n	% who would recommend AL to children under 5	Unadjusted odds ratio and (95% confidence interval; P value)

Paediatric Case Management**

Refer pediatric patients rather than treat

 	Yes	43	49%	2.45 (1.04 - 5.79; 0.041)*

 	No	65	31%	Ref

Refuse Fansidar to a mother requesting it

 	Yes	94	67%	3.59 (1.08 - 11.90; 0.036)*

 	No	19	58%	Ref

	n	% who correctly identified the firstline anti-malarial therapy	Unadjusted odds ratio (95% confidence interval; P value)

Malaria training

Attended malaria workshop

		46	65	0.9

	n	% who correctly identified the firstline anti-malarial therapy	Unadjusted odds ratio (95% confidence interval; P value)

	Yes		%	4 (0.42 - 2.07; 0.873)

	No	66	67%	Ref

Attended malaria workshop after 2006

	Yes	34	62%	0.32 (0.06 - 1.71; 0.184)

	No	12	83%	Ref

Received drug information from MOH

	Yes	94	69%	0.96 (0.85 - 1.08; 0.483)

	No	19	53%	Ref

Dispensing Practices

Recommended AL for uncomplicated malaria in children under 5

	Yes	43	74%	2.41 (1.01 - 5.76; 0.048)*

	No	53	55%	Ref

Recommend AL for uncomplicated malaria in adults

	Yes	55	76%	3.55 (1.49 - 8.47; 0.004)*

	No	42	48%	Ref

Table 4b: Relationship between shop worker recommendation of AL to children under 5 and their response to clinical scenarios

		n	% who would recommend AL to children under 5	Unadjusted odds ratio and (95% confidence interval; P value)

Paediatric Case Management**

Refer pediatric patients rather than treat

	Yes	43	49%	2.45 (1.04 - 5.79; 0.041)*

	No	65	31%	Ref

Refuse Fansidar to a mother requesting it

	Yes	94	67%	3.59 (1.08 - 11.90; 0.036)*

	No	19	58%	Ref


Link	Antecedent	Consequent	Measure(s) of consequent	results

Link found?	Consequent (‘effect’) stronger in DLC?

A	DLC training (DLC sites only)	Staff characteristics	DAS, ADQ, SNCW	Yes	No for DAS, ADQ and parts of SNCW. Yes for SNCW Development and Patient Knowledge components.

Sick-leave	Yes	Yes

Turnover	No	No

B	PDSA cycles	Reported/not reported	Yes	Yes

C	Staff characteristics	Immediate impact of work routines	DCM WIB scores	Partly: for SNCW but not DAS, ADQ.	No

D	PDSA	Yes, but ‘High-WIB’ homes only	Yes, but ‘High-WIB’ homes only

E	Immediate impact of work routines	Quality of life	QUALID	Yes	No

End-of-life care discussion	No	No

End-of-life care plans	No	No

TEP decision forms	No	No

F	Quality of Life	External impacts	Ambulance call-outs	No	No

Emergency admissions	No	No


Characteristic	cv-lysozyme-3	cv-lysozyme-1*	cv-lysozyme-2**

<underline>Lysozyme activity</underline>

 Optimal pH	7.5-8.5	5.5-6.5	5.5-6.5

 Optimal ionic strength (I)	0.005-0.01	0.18-0.20	0.005-0.01

<underline>Antibacterial activity (MIC)</underline>

 E. coli	12.5 μg/mL	1.56 μg/mL	50 μg/mL

 V. vulnificus	ND***	12.5 μg/mL	100 μg/mL

<underline>Molecular properties</underline>

 MW (Dalton)b	17782.3	17861.0	12984.6

 Theoretical pI	6.84 (7.12)	8.95	6.33

<underline>Amino acid sequence</underline>

 Total amino acid number	168	164	117

 Arginine residue number	5	19	5

<underline>Protease cutting sites</underline>

 Trypsin	9	18	9

 Thermolysin	32	28	20

 Pepsin (pH > 2.0)	19	12	5

<underline>Major sites of gene expression</underline>	Digestive glands	Labial palps, mantle	Digestive glands

<underline>Tissues with low mRNA level</underline>	Mantle, labial palps, gill, style sac-midgut, hemocytes	Gill, style sac-midgut, digestive gland, gonad	Style sac-midgut

Characteristic	cv-lysozyme-3	cv-lysozyme-1*	cv-lysozyme-2**

Lysozyme activity

Optimal pH	7.5-8.5	5.5-6.5	5.5-6.5

Optimal ionic strength (I)	0.005-0.01	0.18-0.20	0.005-0.01

Antibacterial activity (MIC)

E. coli	12.5 μg/mL	1.56 μg/mL	50 μg/mL

V. vulnificus	ND***	12.5 μg/mL	100 μg/mL

Molecular properties

MW (Dalton)b	17782.3	17861.0	12984.6

Theoretical pI	6.84 (7.12)	8.95	6.33

Amino acid sequence

Total amino acid number	168	164	117

Arginine residue number	5	19	5

Protease cutting sites

Trypsin	9	18	9

Thermolysin	32	28	20

Pepsin (pH > 2.0)	19	12	5

Major sites of gene expression	Digestive glands	Labial palps, mantle	Digestive glands

Tissues with low mRNA level	Mantle, labial palps, gill, style sac-midgut, hemocytes	Gill, style sac-midgut, digestive gland, gonad	Style sac-midgut


	Utilization of postnatal care

		Confidence interval

Characteristics	Odds ratio	Lower	Upper	p

Occupation

 Agriculture	1

 Service	4.82	1.18	19.62	0.028

 Business	3.47	0.75	16.12	0.112

 Wage laborer	2.88	0.44	18.86	0.270

 Housewife	2.55	0.85	7.62	0.094

Wealth quintile

 Lowest	1

 Second	3.21	0.82	12.52	0.093

 Middle	3.24	0.75	13.94	0.115

 Fourth	7.03	1.87	26.45	0.004

 Highest	7.12	1.84	27.95	0.005

Ethnicity

 Disadvantaged Janajati and Dalit	1

 Newar	0.44	0.18	1.08	0.073

 Brahmin/Chhetri	0.34	0.14	0.84	0.019


Isolate name	rpoBa	Spoligotype classification

R160	Ser531Leu	LCC

R376	Ser531Leu	Haarlem

R458	Ser531Leu	Unknown/unique

R486	Leu533Pro	Beijing

R631	His526Tyr	Unknown/unique

R637	Ser531Leu	Beijing

R641	Leu533Pro	Beijing

R721	Ser531Leu	Beijing

R912	His526Tyr	EAI

R965	Leu533Pro	Beijing

R966	His526Tyr	Beijing

R1035	Ser531Leu	LAM

R1415	His526Tyr	Beijing


Gene	Forward primer (3′-5′)	Product length (bp)	NCBI Genbank	Slope	R2#	Efficiency*

Reverse primer (5′-3′)

Reference genes

ATP5G1	CAGTCACCTTGAGCCGGGCGA	94	NM_001025218	−3.42	0.999	1.96

TAGCGCCCCGGTGGTTTGC

ACTB	GACATCCGCAAGGACCTCTA	205	XM_003124280	−3.60	0.998	1.89

ACATCTGCTGGAAGGTGGAC

RPS9	GTCGCAAGACTTATGTGACC	325	XM_003356050	−3.64	0.999	1.88

AGCTTAAAGACCTGGGTCTG

Target genes

COX4/1	GTGGAACTGTACCGCCTGAA	257	XM_003355730	−3.44	1.000	1.95

TTGTCGTAGTCCCACTTGGC

COX6A1	CTCAGCTCGCATGTGGAAGA	139	NM_001190221	−3.34	0.996	1.99

GATGCGAAGATGGGGGTAGG

CACT/SLC25A20	GCAAAGCCCATTAGCCCTCT	235	XM_003483178	−3.21	0.988	2.05

GAGCACATCCTCTGGGTGTT

PPARGC1A	TAAAGATGCCGCCTCTGACT	168	NM_213963	−3.94	0.993	1.79

TGACCGAAGTGCTTGTTCAG

PPARGC1B	AAGTGCGGCTTCGTCACCTA	216	XM_003124093	−3.28	0.998	2.02

GCTGTCGAAATCCATGGCTT

SLC22A5	TGCATTTGGCTACATGCTGC	174	XM_003123912	−3.76	0.995	1.85

ATGATCACCTCAGCTTCCTG

SDHA	CTACGCCCCCGTCGCAAAGG	380	DQ402993	−3.24	1.000	2.03

AGTTTGCCCCCAGGCGGTTG

MYH2	GGCCCTTTGATGCCAAGACA	188	NM_214136	−3.45	1.000	1.95

GGCCATGTCCTCGATCTTGT

MYH4	GTGCCCTGCTGCCATCAATA	363	NM_001123141	−3.53	1.000	1.92

TGCGTAACGCTCTTTGAGGT

MYH7	TGCCAGCTTGAGCCTCTTTC	380	NM_213855	−3.33	0.999	2.00

GTAGCGCTCCTTGAGGTTGT

FATP1	GGTTCCAGCCTGTTGAATGT	275	NM_001083931	−3.44	0.990	1.95

AACAAAACCTTGGTGCTTGG

UCP2	AGTGTGAGACCTGACGAAGC	435	NM_214289	−3.64	0.996	1.88

GCTTGACGGAGTCGTAGAGG

UCP3	GCCACTTTGTCTCTGCCTTC	219	NM_214049	−3.49	0.998	1.93

CAAACATCACCACGTTCCAG

Gene	Forward primer (3′-5′)	Product length (bp)	NCBI Genbank	Slope	R2#

Reverse primer (5′-3′)

Reference genes

ATP5G1	CAGTCACCTTGAGCCGGGCGA	94	NM_001025218	−3.42	0.999

TAGCGCCCCGGTGGTTTGC

ACTB	GACATCCGCAAGGACCTCTA	205	XM_003124280	−3.60	0.998

ACATCTGCTGGAAGGTGGAC

RPS9	GTCGCAAGACTTATGTGACC	325	XM_003356050	−3.64	0.999

AGCTTAAAGACCTGGGTCTG

Target genes

COX4/1	GTGGAACTGTACCGCCTGAA	257	XM_003355730	−3.44	1.000

TTGTCGTAGTCCCACTTGGC

COX6A1	CTCAGCTCGCATGTGGAAGA	139	NM_001190221	−3.34	0.996

GATGCGAAGATGGGGGTAGG

CACT/SLC25A20	GCAAAGCCCATTAGCCCTCT	235	XM_003483178	−3.21	0.988

GAGCACATCCTCTGGGTGTT

PPARGC1A	TAAAGATGCCGCCTCTGACT	168	NM_213963	−3.94	0.993

TGACCGAAGTGCTTGTTCAG

PPARGC1B	AAGTGCGGCTTCGTCACCTA	216	XM_003124093	−3.28	0.998

GCTGTCGAAATCCATGGCTT

SLC22A5	TGCATTTGGCTACATGCTGC	174	XM_003123912	−3.76	0.995

ATGATCACCTCAGCTTCCTG

SDHA	CTACGCCCCCGTCGCAAAGG	380	DQ402993	−3.24	1.000

AGTTTGCCCCCAGGCGGTTG

MYH2	GGCCCTTTGATGCCAAGACA	188	NM_214136	−3.45	1.000

GGCCATGTCCTCGATCTTGT

MYH4	GTGCCCTGCTGCCATCAATA	363	NM_001123141	−3.53	1.000

TGCGTAACGCTCTTTGAGGT

MYH7	TGCCAGCTTGAGCCTCTTTC	380	NM_213855	−3.33	0.999

GTAGCGCTCCTTGAGGTTGT

FATP1	GGTTCCAGCCTGTTGAATGT	275	NM_001083931	−3.44	0.990

AACAAAACCTTGGTGCTTGG

UCP2	AGTGTGAGACCTGACGAAGC	435	NM_214289	−3.64	0.996

GCTTGACGGAGTCGTAGAGG

UCP3	GCCACTTTGTCTCTGCCTTC	219	NM_214049	−3.49	0.998

CAAACATCACCACGTTCCAG


OTU	No. of clones	Phylogenetic class	Closest cultivated species (% similarity)

Bioreactor for CH4 production

Archaea

 MET-BR-A01	49	Methanobacteria	Methanothermobacter thermautotrophicus (99)

 Total	49

Bacteria

 MET-BR-B01	79	Clostridia	Tepidanaerobacter syntrophicus (93)

 MET-BR-B02	5	Clostridia	Acetivibrio cellulolyticus (91)

 MET-BR-B03	4	Clostridia	Gelria glutamica (98)

 MET-BR-B04	1	Clostridia	Tepidanaerobacter syntrophicus (92)

 MET-BR-B05	1	Clostridia	Desulfosporosinus acidiphilus (95)

 Total	90

Bioreactor for H2 production

Bacteria

 HYD-BR-B01	47	Clostridia	Thermotalea metallivorans (99)

 HYD-BR-B02	10	Clostridia	Tepidanaerobacter syntrophicus (83)

 HYD-BR-B03	9	Flavobacteria	Schleiferia thermophila (88)

 HYD-BR-B04	5	Clostridia	Desulfotomaculum putei (99)

 HYD-BR-B05	5	Clostridia	Desulfotomaculum putei (89)

 HYD-BR-B06	4	Clostridia	Thermosyntropha lipolytica (94)

 HYD-BR-B07	4	Clostridia	Thermotalea metallivorans (99)

 HYD-BR-B08	3	Clostridia	Oxobacter pfennigii (92)

 HYD-BR-B09	3	Clostridia	Clostridium thermosuccinogenes (93)

 HYD-BR-B10	1	Clostridia	Anaerobranca horikoshii (98)

 Total	91

OTU	No. of clones	Phylogenetic class	Closest cultivated species (% similarity)

Total	90

Bioreactor for H2 production

Bacteria

HYD-BR-B01	47	Clostridia	Thermotalea metallivorans (99)

HYD-BR-B02	10	Clostridia	Tepidanaerobacter syntrophicus (83)

HYD-BR-B03	9	Flavobacteria	Schleiferia thermophila (88)

HYD-BR-B04	5	Clostridia	Desulfotomaculum putei (99)

HYD-BR-B05	5	Clostridia	Desulfotomaculum putei (89)

HYD-BR-B06	4	Clostridia	Thermosyntropha lipolytica (94)

HYD-BR-B07	4	Clostridia	Thermotalea metallivorans (99)

HYD-BR-B08	3	Clostridia	Oxobacter pfennigii (92)

HYD-BR-B09	3	Clostridia	Clostridium thermosuccinogenes (93)

HYD-BR-B10	1	Clostridia	Anaerobranca horikoshii (98)

Total	91


	Average (in days)	Within 1 week (in %)	Within 1 month (in %)	Within 3 months (in %)

All scientific fields	39	15	61	92

General	40	14	58	92

Natural sciences	34	17	66	94

Engineering	32	18	71	95

Mathematics and Computer sciences	33	18	69	95

Medicine	38	15	60	93

Public health	29	18	71	99

Psychology	50	12	46	90

Economics and Business	64	3	39	79

Social sciences	50	9	49	87

Humanities	47	10	52	90

	Average (in days)	Within 1 week (in %)	Within 1 month (in %)	Within 3 months (in %)

Engineering	32	18	71	95

Mathematics and Computer sciences	33	18	69	95

Medicine	38	15	60	93

Public health	29	18	71	99

Psychology	50	12	46	90

Economics and Business	64	3	39	79

Social sciences	50	9	49	87

Humanities	47	10	52	90


	MAP-tau expression

Variable	Low (%) (AQUA score < 462)

Menopausal status

Premenopausal	108 (22.8)

Postmenopausal	265 (55.9)

Tumor size

< 2 cm	128 (29.1)

2-5 cm	155 (35.2)

> 5 cm	59 (13.4)

Nuclear grade

Small/uniform nuclei	60 (13.4)

Intermediate nuclei	182 (40.6)

Large nuclei	107 (23.9)

Nodal status

Node positive	199 (41.8)

Node negative	175 (36.8)

ER

Negative	227 (48.6)

Positive	140 (29.9)

PR

Negative	240 (52.4)

Positive	120 (26.2)

HER2

Negative	283 (61.3)

Positive	80 (17.3)


Type or gene involved	Number	Mean, kb	Range, kb

Copy number losses : large

 Interstitial deletion	18	5,070	1,048–16,837

 Terminal deletion	14	5,273	1,218–13,593

 Unbalanced translocation	15	7,053	880–17,107

 Subtotal	47

Copy number losses: small

 DOCK8	24	299	97–431

 KANK1	3	369	184–670

 DOCK8 and KANK1	3	419	75–676

 EHMT1	16	417	22–790

 ASTN2	4	150	78–271

 FREM1	2	369	166–573

 STXBP1	1	592	NA

 COL5A1	1	370	NA

 GLDC	1	50	25–75

 TOPORS	1	337	NA

 CDK5RAP2	1	74	NA

Subtotal	57

Large copy number gains

 Trisomy 9p/proximal 9q	15	45,996	13,826–95,453

 9q duplications	6	12,172	6,277–18,399

 Unbalanced translocation	4	25,717	6,794–68,089

 Tetrasomy 9q and proximal 9q due to isochromosome	3	66,477	49,843–81,113

 Trisomy 9	2	140,833	NA

 Triplication	1	15,972	NA

 Subtotal	31

Complex chromosomal rearrangements (CCRs)

 Inverted duplication with terminal deletion of 9p	3	Deletion: 6,377; Duplication: 32,271

 Inverted duplication with terminal deletion of 9q	1	Deletion: 161; Duplication: 3,127

 Multiple deletion and duplication	2	Losses: 1091; Gains: 12,517

 Chromothripsis	1	Loss: 134; Gains: 21,094

 Subtotal	7

 Total	142

Type or gene involved	Number	Mean, kb	Range, kb

Chromothripsis	1	Loss: 134; Gains: 21,094

Subtotal	7

Total	142


Age group of children (months)	Rotavirus status of Children

		Positive	Negative	Total	P-value

0-6	count	2	8	10

	% of total	1.3%	5.0%	6.3%

7-12	count	12	40	52

	% of total	7.5%	25.0%	32.5%	0.047

13-24	count	6	54	60

	% of total	3.8%	33.8%	37.5%

25-60	count	2	36	38

	% of total	1.3%	22.5%	23.8%

Total	count	22	138	160

	% of total	13.8%	86.2%	100.0%

Age group of children (months)	Rotavirus status of Children

		Positive	Negative	Total	P-value

Total	count	22	138	160

	% of total	13.8%	86.2%	100.0%


Dataset		#Subjects	#Case	Platform	#SNPs

Croatia	(Before QC)	306	103	Illumina 550 K	561,466

	(After QC)	305	103		489,200

NINDS	(Before QC)	542	0	Illumina 550 K	561,466

	(After QC)	534	0		489,096

HGDP	(Before QC)	1,043	0	Illumina 650Y	660,918

	(After QC)	1,043	0		584,835

		Merged datasets

Croatia+NINDS	(After QC)	839	103	-	475,964

Croatia+HGDP	(After QC)	1,348	103	-	478,287

Dataset		#Subjects	#Case	Platform

Croatia	(Before QC)	306	103	Illumina 550 K

	(After QC)	305	103

NINDS	(Before QC)	542	0	Illumina 550 K

	(After QC)	534	0

HGDP	(Before QC)	1,043	0	Illumina 650Y

	(After QC)	1,043	0

		Merged datasets

Croatia+NINDS	(After QC)	839	103	-

Croatia+HGDP	(After QC)	1,348	103	-


Species	Female	Male

Dichaetophora acutissima	20	25

Drosophila annulipes	31	27

Drosophila bizonata	31	31

Drosophila busckii	35	41

Drosophila curviceps	20	26

Drosophila hydei	11	20

Drosophila immigrans	41	41

Drosophila lutescens	14	42

Drosophila rufa	41	41

Drosophila sternopleuralis	42	42

Drosophila suzukii	22	19

Hirtodrosophila sexvittata	41	41

Liodrosophila aerea	41	41

Microdrosophila sp.	15	10

Scaptodrosophila coracina	5	34

Scaptomyza graminum	36	32


	Arabidopsis	Rice

Origin of nat-siRNAs	Total	Unique	Total	Unique

Entire NATs	33,826	17,059	162,397	56,209

 Introns in entire NATs	14,500	6,988	88,605	29,654

OR of NATs	10,429	6,532	27,852	10,761

Introns in OR of NATs	4,367	2,350	14,207	5,494

	Arabidopsis	Rice

Origin of nat-siRNAs	Total	Unique	Total	Unique

Introns in OR of NATs	4,367	2,350	14,207	5,494


Sample	Potential (mV)	Dissolution Current Density at −400 mV (A cm−2)

No Exposure	−486.5	1.3 × 10−4

Arica	−574.7	4.0 × 10−4

Quintero	−611.1	12 × 10−4

Laja	−515.0	1.6 × 10−4

Antarctic	−548.7	4.6 × 10−4

Sample	Potential (mV)

No Exposure	−486.5

Arica	−574.7

Quintero	−611.1

Laja	−515.0

Antarctic	−548.7

Dissolution Current Density at −400 mV (A cm−2)

1.3 × 10−4

4.0 × 10−4

12 × 10−4

1.6 × 10−4

4.6 × 10−4


					It is likely that people who

					have consumed bushmeat in

Variable	Response	Estimatea	SE	RVIb	the year prior to survey...

ARUc	yes	−0.652	0.218	1.00	are not ARUs

Marital status	single	0.619	0.216	0.99	are from single parent households

Benefit from MUPd	yes	0.424	0.172	0.95	have benefitted from MUP

Well‐beinge	somewhat bad	0.030	0.223	0.95	rate their lives average or somewhat bad

	worst	−0.644	0.319

Education	4 years or more	−0.309	0.174	0.45	have 3 or fewer years of formal education


Gene	GC% M. davidii	GC% P. alecto	Gene length M. davidii	Gene length P. alecto

IKZF1	49.6	53.2 / 51.5	1908	228/816

GPSM1	49.1	65.4	705	2118

SPRR1	44.0	47.1	339	342

Gene length M. davidii	Gene length P. alecto

1908	228/816

705	2118

339	342


Clinicopathological parameters	n	NgBR expression	P

Low	High

Age (y)

	≤ 54	47	22	25	0.051

	> 54	42	11	31

Gender

	Male	80	29	51	0.906

	Female	9	4	5

Hepatitis history

	No	27	8	19	0.474

	Yes	62	25	37

Cirrhosis

	No	27	8	19	0.474

	Yes	62	25	37

Tumor size

	≤ 5 cm	38	13	25	0.306

	> 5 cm	51	20	31

Tumor number

	Single	46	15	31	0.389

	Multiple	43	18	25

Vascular invation

	No	78	30	48	0.700

	Yes	11	3	8

TNM stage

	I + II	46	19	27	0.511

	III + IV	43	14	29

Clinicopathological parameters	n	NgBR expression	P

Low	High

	> 5 cm	51	20	31

Tumor number

	Single	46	15	31	0.389

	Multiple	43	18	25

Vascular invation

	No	78	30	48	0.700

	Yes	11	3	8

TNM stage

	I + II	46	19	27	0.511

	III + IV	43	14	29


	Parameter

GROUP	Norepinephrine	Dopamine	Serotonin

Control	0.376 ± 0.07	1.45 ± 0.12	0.80 ± 0.115

Leaded gasoline	0.47 ± 0.086 a*	1.71 ± 0.14 a*	0.60 ± 0.043 a**

Unleaded gasoline	0.41 ± 0.036	1.35 ± 0.24 b**	0.385 ± 0.057 a*** b**


MIGS ID	Characteristic	Details

MIGS-28	Libraries used	2kb (pUC19) and 40kb (pcc1FOS) Sanger and 454 standard libraries

MIGS-29	Sequencing platform	ABI-3730, 454 GS FLX Titanium

MIGS-31.2	Sequencing coverage	1.1× Sanger 40kb insert, 31.3× pyrosequencing

MIGS-31	Finishing Quality	Finished

MIGS-30	Assembler	gsAssembler (Newbler) version 2.5.3

MIGS-32	Gene calling method	IMG-ER pipeline [27](CRISPR: CRT [28] and PILERCR [29];tRNAs: tRNAScan-SE-1.23 [30]; rRNA: RNAmmer [31];other genes: Prodigal [32])

	GenBank ID	CP003985, CP003986

	GenBank date of release	14.01.2013

	GOLD ID	Gi18068

	NCBI project ID	91121

	IMG Taxon ID	2512875001

MIGS-13	Source material identifier	DSM 10523T

	Project relevance	Sulfur cycle


Criteria	Percentage

WHO	61.43%

Not sure	17.14%

ADA	12.38%

IADPS	9.05%

Criteria	Percentage

WHO	61.43%

Not sure	17.14%

	12.38%


	Coefficient of drug interaction (CDI)

Etoposide	Epirubicin	Doxorubicin	Vincristine	Colchicine

Ad5GS3	0.27	0.31	0.33	0.89	0.78

Ad5WS1	0.67	0.46	0.88	0.79	0.81

	Coefficient of drug interaction (CDI)

Etoposide	Epirubicin	Doxorubicin	Vincristine

Ad5GS3	0.27	0.31	0.33	0.89

Ad5WS1	0.67	0.46	0.88	0.79

Coefficient of drug interaction (CDI)

Colchicine

0.78

0.81


Exophily	No. caught	Exiting % (95% CI)	Median IQR exiting	OR	95% CI	P-value	Z

Control net

West African hut	587	35 (31–39)	2 (0.5–3)	1


		WT	AS5ox-1	AS5ox-2

*Days to Flowering from Planting	50.60 ± 1.43	53.80 ± 0.79	53.80 ± 0.79

*Total Chlorophyll (g/m2) at Maturity	0.75 ±	0


Wired	Wireless

High bandwidth	Low-medium bandwidth

High performance	Higher latency

Robust	Interference

Reliable	Unreliable by nature

Installation expensive	Installation cheap

“Unlimited” resources	Low power, memory

Static network	Mobile network

Less security problems	More security problems


ALT (U/L)	AST (U/L)	Alkaline Phosphatase (U/L)	Total Billirubin (mg/dL)


Dose, Subgroup (n at final visit)	Physical ComponentSummary	Mental ComponentSummary	Mental HealthDomain

Elderly

1 mg, with psychiatric disorders (n = 37)a

Baseline	40.9 (15.9)	43.6 (9.9)	39.5 (12.2)


Training section	Examples for tasks

Planning strategies	Shopping lists, key search of the BADS subscales, to get items out of a bottle, special wooden 3-dimensional jig saw

Mnemonics	Using memory hooks, writing of suitable mnemonics, and planning where to place them

Decision making	Computer tasks, painting

Set shifting	To solve various tasks according to changing rules, to calculate for 5 min, then to read for 10 min and to write for 5 min, or to switch tasks after every third answer, categorising items according to different rules

Calculation	Calculation tasks

Navigational skills	Finding the way through a maze on a screen, finding the way around obstacles on a paper or on a screen

Information speed processing	Connecting numbers or letters, connecting figures to an image, and finding the meaning of a fictive word

Summary	Extracting the relevant information from news or from a story or a short movie

Concentration	 Finding similar or dissimilar items

Training section

Planning strategies

Mnemonics

Decision making

Set shifting

Calculation

Navigational skills

Information speed processing

Summary

Concentration

Examples for tasks

Shopping lists, key search of the BADS subscales, to get items out of a bottle, special wooden 3-dimensional jig saw

Using memory hooks, writing of suitable mnemonics, and planning where to place them

Computer tasks, painting

To solve various tasks according to changing rules, to calculate for 5 min, then to read for 10 min and to write for 5 min, or to switch tasks after every third answer, categorising items according to different rules

Calculation tasks

Finding the way through a maze on a screen, finding the way around obstacles on a paper or on a screen

Connecting numbers or letters, connecting figures to an image, and finding the meaning of a fictive word

Extracting the relevant information from news or from a story or a short movie

Finding similar or dissimilar items


Gene		N	Mean ± SD	P-value (Mann-Whitney test)

APC	Cases	11	2.06 ± 2.6	0.3

	Controls	10	0.95 ± 1.31

ATM	Cases	9	0.5 ± 0.9	0.9

	Controls	10	1.48 ± 2.2

Gene		N	Mean ± SD	P-value (Mann-Whitney test)

ATM	Cases	9	0.5 ± 0.9	0.9

	Controls	10	1.48 ± 2.2


Variable	N

Age (yrs)	51	66.7 (12.0)

Sex (M/F)	51	26/25

MMSE	51	28.7 (1.4)

Education	51	5 (2)

NRS 50 kPa 	51	1.2 (1.6)

NRS 200 kPa 	51	2.9 (2.3)

NRS 400 kPa	51	5.0 (2.6)

Facial expressions 50 kPa 	51	0.4 (0.6)

Facial expressions 200 kPa 	50	0.7 (0.9)

Facial expressions 400 kPa	51	1.2 (1.4)

Stroop Word card (s)	51	55.9 (15.9)

Stroop Color card (s)	51	67.3 (20.1)

Stroop Color/Word card (s)	51	127.5 (95.2)

Zoo Map score	51	11.0 (4.0)

Digit Span Backward	51	5.8 (2.3)

AVLT immediate recall	51	38.6 (11.1)

AVLT delayed recognition	51	27.3 (2.9)

RBMT immediate story recall	51	7.5 (3.4)

RBMT delayed story recall 	51	6.3 (3.2)

Variable	N

Facial expressions 50 kPa	51	0.4 (0.6)

Facial expressions 200 kPa	50	0.7 (0.9)

Facial expressions 400 kPa	51	1.2 (1.4)

Stroop Word card (s)	51	55.9 (15.9)

Stroop Color card (s)	51	67.3 (20.1)

Stroop Color/Word card (s)	51	127.5 (95.2)

Zoo Map score	51	11.0 (4.0)

Digit Span Backward	51	5.8 (2.3)

AVLT immediate recall	51	38.6 (11.1)

AVLT delayed recognition	51	27.3 (2.9)

RBMT immediate story recall	51	7.5 (3.4)

RBMT delayed story recall	51	6.3 (3.2)


Characteristic	Value

Blood flow (ml/min)a	421 ± 42

Time of utilization (h)	30.6 ± 21.0

Access pressure (mmHg)a	− 145 ± 14

Filter pressure (mmHg)a	301 ± 19

Return pressure (mmHg)a	154 ± 21

Heparin bolus at insertion (IU)	3100 ± 1330

Heparin (IU/kg/24 h)	230 ± 78

Activated partial thromboplastin time ratio	1.8 ± 0.6

Serious adverse eventb

 Nonfatal cardiac arrest	1 (5)

Study-related adverse event

 Mild hemoptysis resolved with stopping anticoagulationc	2 (10)

 Membrane clotting	10 (50)

Time it occurred (h)	20.0 ± 9.7